Guidelines for Canadian Drinking Water Quality:
Guideline Technical Document

Trihalomethanes

Prepared by the
Federal-Provincial-Territorial Committee on Drinking Water of the
Federal-Provincial-Territorial Committee on Health and the Environment

Health Canada
Ottawa, Ontario

May 2006
(with April 2009 addendum)
This document supersedes previous guideline technical documents (formerly known as supporting documents) on trihalomethanes in drinking water. It may be cited as follows:


The document was prepared by the Federal-Provincial-Territorial Committee on Drinking Water of the Federal-Provincial-Territorial Committee on Health and the Environment.

Any questions or comments on this document may be directed to:

Water Quality and Health Bureau
Healthy Environments and Consumer Safety Branch
Health Canada
269 Laurier Avenue West, Address Locator 4903D
Ottawa, Ontario
Canada K1A 0K9

Tel.: 613-948-2566
Fax: 613-952-2574
E-mail: water_eau@hc-sc.gc.ca

Other Guideline Technical Documents for the Guidelines for Canadian Drinking Water Quality can be found on the Water Quality and Health Bureau web page at http://www.healthcanada.gc.ca/waterquality
Table of Contents

ADDENDUM ................................................................. vi
1.0 Guidelines ................................................................. 1
   Trihalomethanes .......................................................... 1
   Bromodichloromethane .................................................. 1
   Other Considerations ................................................... 1

2.0 Executive summary ...................................................... 1
   2.1 Health effects ....................................................... 2
   2.2 Exposure ........................................................... 2
   2.3 Treatment .......................................................... 3

3.0 Application of the guidelines ........................................... 3
   3.1 Monitoring ......................................................... 4

4.0 Identity, use and sources in the environment ......................... 5
   4.1 Formation of THMs during disinfection .............................. 5

5.0 Exposure ................................................................. 6
   5.1 Water ............................................................. 6
   5.2 Multi-route exposure through drinking water .................... 7
   5.3 Food and beverages ................................................ 8
   5.4 Consumer products ............................................... 9
   5.5 Swimming pools and hot tubs ..................................... 9
   5.6 Estimates of total exposure to chloroform ....................... 9

6.0 Analytical methods ....................................................... 10

7.0 Treatment technology .................................................... 11
   7.1 Municipal-scale ..................................................... 11
      7.1.1 Removal of precursors prior to municipal disinfection ...... 12
      7.1.2 Alternative municipal disinfection strategies ............... 12
   7.2 Residential scale .................................................. 13
      7.2.1 Filtration devices ........................................... 14
      7.2.2 Alternative residential disinfection strategies ............. 14

8.0 Kinetics and metabolism ................................................ 14
   8.1 Absorption ......................................................... 14
      8.1.1 Chloroform .................................................. 15
   8.2 Distribution ....................................................... 15
      8.2.1 Chloroform .................................................. 15
      8.2.2 Brominated trihalomethanes ................................. 15
8.3 Metabolism .............................................................. 15
  8.3.1 Chloroform .......................................................... 15
  8.3.2 Brominated .......................................................... 16
  8.3.3 Mixtures of THMs .................................................. 17
8.4 Excretion ................................................................. 18
  8.4.1 Chloroform .......................................................... 18
  8.4.2 Bromodichloromethane ........................................... 18
8.5 PBPK models ............................................................. 18
  8.5.1 Chloroform .......................................................... 18
  8.5.2 Bromodichloromethane ........................................... 20

9.0 Effects in humans .................................................... 20
  9.1 Cancer epidemiology .................................................. 20
  9.2 Reproductive epidemiology .......................................... 22

10.0 Effects on experimental animals and in vitro .......................... 24
  10.1 Acute toxicity ....................................................... 24
  10.2 Subchronic toxicity ................................................ 24
    10.2.1 Trihalomethanes .............................................. 24
    10.2.2 Chloroform ................................................... 25
    10.2.3 Bromodichloromethane ...................................... 27
    10.2.4 Dibromochloromethane ...................................... 28
    10.2.5 Bromoform ................................................... 28
  10.3 Genotoxicity ........................................................ 29
    10.3.1 Trihalomethanes .............................................. 29
    10.3.2 Chloroform ................................................... 29
    10.3.3 Bromodichloromethane ...................................... 29
    10.3.4 Dibromochloromethane ...................................... 29
    10.3.5 Bromoform ................................................... 30
  10.4 Chronic toxicity/carcinogenicity .................................. 30
    10.4.1 Chloroform ................................................... 30
    10.4.2 Mechanism of carcinogenicity for chloroform ............... 32
    10.4.3 Bromodichloromethane ...................................... 35
    10.4.4 Dibromochloromethane ...................................... 36
    10.4.5 Bromoform ................................................... 37
  10.5 Reproductive and developmental toxicity .......................... 38
    10.5.1 Trihalomethanes .............................................. 38
    10.5.2 Chloroform ................................................... 38
    10.5.3 Bromodichloromethane ...................................... 39
    10.5.4 Dibromochloromethane ...................................... 40
    10.5.5 Bromoform ................................................... 41
  10.6 Neurotoxicity ................................................................ 41
11.0 Classification and assessment ............................................. 41
  11.1 Trihalomethanes (chloroform) ........................................... 41
  11.2 Bromodichloromethane ............................................ 43
  11.3 Dibromochloromethane ............................................ 46
  11.4 Bromoform ...................................................... 46

12.0 Rationale ............................................................. 46
  12.1 Trihalomethanes (chloroform) ...................................... 47
  12.2 Bromodichloromethane ............................................ 47

13.0 References ............................................................ 48

Appendix A: List of acronyms ................................................... 61
The guideline technical document (GTD) for trihalomethanes (THMs), which was published in 2006, also includes a specific guideline for bromodichloromethane (BDCM). The maximum acceptable concentration (MAC) for THMs is based on the health effects of chloroform, and applies to the total concentration of chloroform, BDCM, dibromochloromethane and bromoform.

Since the publication of the GTD, several new scientific papers have been published on the health effects of BDCM and of THMs. As these articles were considered to have a potential bearing on the existing guideline values, a panel of experts was convened in September 2008 to provide expert advice and to make recommendations to Health Canada and to the Federal-Provincial-Territorial Committee on Drinking Water (CDW) regarding BDCM in drinking water.

Based on Health Canada’s re-assessment of the overall weight of scientific evidence and on the findings and recommendations of the Expert Panel1 on BDCM, the Federal-Provincial-Territorial CDW recommended rescinding the separate guideline for BDCM. The guideline for THMs is now considered sufficient on its own to protect for potential adverse health effects related to the exposure to BDCM in drinking water. The new information on BDCM will be added in the GTD for THMs during the next update of the document.

Effective April 2009, the guideline statement for trihalomethanes in drinking water is modified to remove the separate guideline for BDCM, recognizing that the maximum acceptable concentration for THMs is protective of the health effects of all THMs, including BDCM. The revised Guideline statement reads as follows:

**Trihalomethanes**

*The maximum acceptable concentration (MAC) for trihalomethanes (THMs) in drinking water is 0.100 mg/L (100 µg/L) based on a locational running annual average of a minimum of quarterly samples taken at the point in the distribution system with the highest potential THM levels.*

Utilities should make every effort to maintain concentrations as low as reasonably achievable without compromising the effectiveness of disinfection.

---

1The Findings and Recommendations of the Expert Panel are available upon request. To obtain a copy, please send an e-mail to water_eau@hc-sc.gc.ca.

*Guidelines for Canadian Drinking Water Quality: Guideline Technical Document*
Trihalomethanes

1.0 Guidelines

Trihalomethanes

The maximum acceptable concentration (MAC) for trihalomethanes\(^1\) (THMs) in drinking water is 0.100 mg/L (100 µg/L) based on a locational running annual average of a minimum of quarterly samples taken at the point in the distribution system with the highest potential THM levels.

Bromodichloromethane

The maximum acceptable concentration (MAC) for bromodichloromethane (BDCM) in drinking water is 0.016 mg/L (16 µg/L) monitored at the point in the distribution system with the highest potential THM levels.

Other Considerations

Utilities should make every effort to maintain concentrations as low as reasonably achievable without compromising the effectiveness of disinfection.

2.0 Executive summary

Trihalomethanes are a group of compounds that can form when the chlorine used to disinfect drinking water reacts with naturally occurring organic matter (e.g., decaying leaves and vegetation). The use of chlorine in the treatment of drinking water has virtually eliminated waterborne diseases, because chlorine can kill or inactivate most microorganisms commonly found in water. The majority of drinking water treatment plants in Canada use some form of chlorine to disinfect drinking water: to treat the water directly in the treatment plant and/or to maintain a chlorine residual in the distribution system to prevent bacterial regrowth. The health risks from disinfection by-products, including trihalomethanes, are much less than the risks from consuming water that has not been disinfected. Utilities should make every effort to maintain concentrations of all disinfection by-products as low as reasonably achievable without compromising the effectiveness of disinfection.

The trihalomethanes most commonly found in drinking water are chloroform, bromodichloromethane (BDCM), dibromochloromethane (DBCM) and bromoform. Of these, chloroform has been most extensively studied, and there are some scientific data available on BDCM. However, insufficient data are available to develop a guideline for either DBCM or bromoform. Since chloroform is the trihalomethane most often found in drinking water, and

\(^1\) Trihalomethanes refers to the total of chloroform, bromodichloromethane, dibromochloromethane and bromoform compounds.
generally at the highest concentrations, the trihalomethane guideline is based on health risks linked to chloroform. This guideline applies to the total concentration of chloroform, BDCM, DBCM and bromoform.

This Guideline Technical Document reviews all the health risks associated with trihalomethanes in drinking water, incorporating multiple routes of exposure to trihalomethanes via drinking water including ingestion, and both inhalation and skin absorption from showering and bathing. It assesses all identified health risks, taking into account new studies and approaches, and applies appropriate safety factors. Based on this review, the guideline for total trihalomethanes in drinking water is established at a maximum acceptable concentration of 0.1 mg/L.

Although the concentration of BDCM is included in the concentration of trihalomethanes in the guideline, a separate guideline for BDCM is also deemed necessary. The guideline for bromodichloromethane in drinking water is established at a maximum acceptable concentration of 0.016 mg/L.

2.1 Health effects

Chloroform is considered to be a possible carcinogen in humans, based on limited evidence in experimental animals, and inadequate evidence in humans. Animal studies have shown links between exposure to specific trihalomethanes and liver tumours in mice and kidney tumours in both mice and rats; some studies in humans show data that are consistent with these findings. Human studies are suggesting a link between exposure to trihalomethanes and colorectal cancers.

Human studies also suggest a link between reproductive effects and exposure to high levels of trihalomethanes. However, an increase in the concentration of trihalomethanes could not be linked to an increase in risk, suggesting the need for more studies.

Preliminary animal studies indicate that BDCM and other trihalomethanes that contain bromine may be more toxic than chlorinated trihalomethanes such as chloroform. For this reason, and based on the availability of scientific data for BDCM, a separate guideline was also developed for BDCM. BDCM is considered to be a probable carcinogen in humans, with sufficient evidence in animals and inadequate evidence in humans. Animal studies have shown tumours in the large intestine in rats. Among the four trihalomethanes commonly found in drinking water, BDCM appears to be the most potent rodent carcinogen, causing tumours at lower doses and at more target sites than the other three compounds.

Exposure to BDCM at levels higher than the guideline value has also been linked to a possible increase in reproductive effects (increased risk for spontaneous abortion or stillbirth) above what can normally be expected. Further studies are required to confirm these effects.

2.2 Exposure

Levels of trihalomethanes, including BDCM, are generally higher in treated surface water than in treated groundwater, because of the high organic content in lakes and rivers, and will be higher in warmer months, because of the higher concentrations of precursor organic materials in the raw water and especially because the rate of formation of disinfection by-products increases at higher temperatures. Trihalomethanes levels are also affected by the choice and design of treatment processes. Recent data indicate that, in general, average trihalomethanes
levels in Canadian drinking water supplies are well below the guideline. However, some systems show average levels well above the guidelines; these systems serve only a small proportion of Canadians (less than 4%) and are generally smaller treatment systems with limited ability to remove organic matter before adding the chlorine disinfectant. It should be noted that the presence of brominated by-products such as BDCM will also depend on the presence of bromine in the source water.

2.3 Treatment
Trihalomethanes and haloacetic acids are the two major groups of disinfection by-products found in drinking water and generally at the highest levels. Together, these two groups can be used as indicators for the presence of all disinfection by-products in drinking water supplies, and their control is expected to reduce the levels of all disinfection by-products and the corresponding risks to health. A guideline for haloacetic acids is expected to be available in 2006–2007.

The approach to reduce exposure to trihalomethanes is generally focused on reducing the formation of chlorinated disinfection by-products. The concentrations of trihalomethanes and other chlorinated disinfection by-products in drinking water can be reduced at the treatment plant by removing the organic matter from the water before chlorine is added, by optimizing the disinfection process or using alternative disinfection strategies, or by using a different water source. It is critical that any method used to control trihalomethanes levels must not compromise the effectiveness of disinfection. The Federal-Provincial-Territorial Committee on Drinking Water also recommends that every effort be made not only to meet the guideline, but to maintain concentrations of trihalomethanes as low as reasonably achievable.

3.0 Application of the guidelines
Note: Specific guidance related to the implementation of the guidelines should be obtained from the appropriate drinking water authority in the affected jurisdiction.

Guidelines for drinking water contaminants are usually developed using the results of animals studies. The guideline for total THMs is based on the health effects of chloroform, which is now classified as a possible human carcinogen (changed from its previous classification of “probable” human carcinogen). It incorporates uncertainty factors to account for a range of issues, including differences within and across species, deficiencies in the database and some limited evidence of carcinogenicity. Because of the limitations in current scientific methodology, it is not possible to quantify the increased risk to human health when a drinking water supply exceeds the guideline value.

The guideline for THMs is also designed to take into consideration exposure and potential health effects related to other disinfection by-products (DBPs), on which very little is known. It represents a level of exposure that is acceptable throughout life (70 years) and that will not cause an increased risk to health. It takes into account all exposures from drinking water (whether by ingestion, inhalation or dermal absorption). The guideline is measured as a locational running annual average of quarterly samples, because THM levels can vary significantly over time, including seasonally, with factors such as the levels of organic matter in
the raw water and temperature. Although individual measurements may exceed the guideline value, this would be of concern only if they caused the running average of quarterly samples to exceed the guideline value.

BDCM is a probable human carcinogen, which means that exposure to any level in drinking water may increase the risk of cancer. The guideline is established at a level at which the increased cancer risk is “essentially negligible” when humans are exposed at that level over a lifetime (70 years). In the context of drinking water guidelines, Health Canada has defined this term as a range from one new cancer above background per 100,000 people to one new cancer above background per 1 million people (i.e., $10^{-5}$ to $10^{-6}$) over a lifetime. Exposure to BDCM at levels higher than the guideline value has also been linked to a possible increase in reproductive effects (increased risk for spontaneous abortion or stillbirth) above what can normally be expected in the population although further studies are required to confirm these effects. However, where BDCM exceeds the guideline value, a jurisdiction may decide to take action to reduce levels of BDCM and, may choose to take further precautionary steps on the basis of these studies to protect populations believed to be vulnerable. The guideline for BDCM is protective of both cancer and non-cancer health effects.

Both drinking water guidelines are protective against health effects from lifelong exposure. However, as with all guidelines, any significant exceedance should be a signal to investigate the situation in order to take remedial action and to consult the authority responsible for public health. For significant exceedances above the guideline value, it is suggested that a plan be developed and implemented to address these situations.

Given the potential health effects from THMs, including BDCM, and the limited information on the risks and uncertainties of other chlorinated disinfection by-products (CDBPs), it is recommended that treatment plants strive to maintain THM and BDCM levels as low as reasonably achievable (or ALARA) without compromising disinfection. Treatment plants also need to ensure that any effort aimed at reducing disinfection by-products, such as changing disinfection strategies, does not inadvertently increase the levels or leaching of other contaminants, such as lead, in the distributed water.

### 3.1 Monitoring

At minimum, quarterly monitoring of treated water from surface water and groundwater sources is recommended for both THMs and BDCM. Increased frequency may be required for facilities using surface water sources\(^2\) during peak by-product formation periods. It is also recommended that monitoring samples be taken at the water treatment plant and at the point in the distribution system with the highest THM formation potential. These points generally represent the areas in the distribution system with the longest disinfectant retention time, which are typically at the far end of the distribution system.

Monitoring/reporting may be reduced if drinking water monitoring does not show elevated levels of CDBPs within the distribution system.

---

\(^2\) Includes groundwater sources that are under the direct influence of surface water
4.0 Identity, use and sources in the environment

Trihalomethanes (THMs) are halogen-substituted single-carbon compounds with the general formula CHX₃, where X represents a halogen, which may be chlorine, bromine, fluorine, or iodine, or combinations thereof. The THMs most commonly present in drinking water are chloroform (CHCl₃), bromodichloromethane or dichlorobromomethane (CHBrCl₂) (BDCM), dibromochloromethane or chlorodibromomethane (CHClBr₂) (DBCM), and bromoform (CHBr₃); consideration of information relevant to the derivation of drinking water guidelines for THMs is restricted to these compounds. THM measurement assesses these four common THMs, with chloroform usually constituting the largest proportion. As well as being the most common THM, chloroform is also the principal DBPs in chlorinated drinking water (LeBel and Williams, 1995).

These compounds are formed in drinking water primarily as a result of chlorination of organic matter present naturally in raw water supplies, and they are released into the environment from industrial sources as well as through indirect production in the chlorination of drinking water and municipal sewage. The rate and degree of THM formation increase as a function of the chlorine and humic acid concentration, temperature, pH, and bromide ion concentration (Stevens et al., 1976; Amy et al., 1987). In the presence of bromides, brominated THMs are formed preferentially and chloroform concentrations decrease proportionally (Aizawa et al., 1989).

The four compounds considered here are liquids at room temperature. They are relatively to extremely volatile, with vapour pressures at 25°C ranging from 0.80 kPa for bromoform to 23.33 kPa for chloroform. The THMs are only slightly soluble in water, with solubilities less than 1 mg/mL at 25°C. Their log octanol–water partition coefficients range from 1.97 (chloroform) to 2.38 (bromoform). Chloroform decomposes via photochemical oxidation to dichlorocarbonyl (phosgene) and hydrogen chloride (Environment Canada and Health Canada, 2001).

Chloroform has not been manufactured in Canada since 1978, and its use as an anaesthetic has been largely discontinued. The presence of chloroform in dentifrices, liniments, and antitussives has contributed to the exposure of Canadians in the past, but the use of chloroform in these products has now been banned under the Food and Drugs Act. Manufacturers are not permitted to import or sell a drug that contains chloroform for human use in Canada (Environment Canada and Health Canada, 2001). Canadian imports of chloroform were 402 tonnes in 1993, 69 tonnes in 1995, and 118 tonnes in 1996, with imports declining in recent years. Chloroform is used as a solvent and in the production of other chemicals (Environment Canada and Health Canada, 2001). BDCM is used in the synthesis of other chemicals and as a solvent, whereas DBCM is an intermediate in the manufacture of refrigerants, pesticides, propellents, and other organic chemicals (Keith and Walters, 1985). Bromoform is used in the synthesis of pharmaceuticals, as a solvent, and in the aircraft and shipbuilding industries as an ingredient in fire-resistant chemicals and gauge fluid.

4.1 Formation of THMs during disinfection

The formation of CDBPs is a complex process that occurs when chlorine reacts with naturally present organic matter. The process is a function of naturally occurring organic precursor concentration, chlorine dose, contact time, water pH and temperature, and bromide ion
concentration. An important parameter in CDBP formation is pH: THM formation increases at high pH and decreases at low pH, whereas the formation of haloacetic acids (HAAs) (the second most common group of disinfection by-products) decreases at high pH and increases at low pH. Therefore, some remedial measures applied to minimize THM formation could potentially maximize the formation of other CDBPs.

Results from Health Canada studies (Williams et al., 1995, 1997; LeBel et al., 1996, 1997), including a national survey of CDBPs in Canadian drinking water (53 systems) and a 1-year monthly survey of three systems using different disinfection processes, indicated that THMs and HAAs were the major CDBPs found in all facilities for all treatment processes including chlorine disinfectant, and that HAA levels often equalled or exceeded THM concentrations. The CDBPs levels and variation were also dependent on the DBP group, temperature (seasonal variation), water sampling location within the distribution system (contact time, spatial variation), and type of disinfection (chlorination, chloramination, ozonation). Also, within a CDBP group, the bromo-chloro speciation was dependent on the bromide ion level in water.

5.0 Exposure

5.1 Water

Although extensively studied, the chemistry of the reactions between chlorine and the organic materials present in water is complex and poorly understood; however, important factors include naturally occurring organic precursor concentration, chlorine dose, contact time, water pH and temperature, and bromide ion concentration. Consequently, there is a great degree of variation in the measured concentrations of THMs in drinking water.

Levels of chloroform, the most common THM, are generally higher in chlorinated water originating from surface water compared with groundwater, because of higher organic matter in the former. The extent of formation of chloroform varies with different water treatment processes. Concentrations of chloroform in chlorinated water in treatment plants and distribution systems are approximately twice as high during summer months as during winter months. This is a consequence of the higher concentrations of precursor organic materials in the raw water during the warmer period and especially because the rate of formation of DBPs increases with rising temperatures (LeBel et al., 1997). Levels can increase as the chlorinated water moves from the water treatment plant through the distribution system, because of the continued presence of a chlorine residual. Further increases in concentrations of chloroform in water can occur in domestic hot water tanks. However, storage in the hot water tank increases the level of chloroform twice as much in the winter, when more hot water is required to maintain the shower temperature, as in the summer, so that concentrations of chloroform in the warm water used for showering are relatively constant in both seasons (Williams et al., 1995; Benoit et al., 1997).

Concentrations of THMs have been determined in drinking water supplies at a considerable number of locations across Canada (Water Quality Issues Sub-Group, 2003). Eight provinces provided 1994–2000 THM data for just over 1200 water systems serving a sampled population of over 15 million Canadians. The methods of sampling and analysis varied and were often not well described, but generally samples were taken from the midpoints and/or endpoints of the water systems, and the typical methods of analysis were either liquid–liquid extraction or purge-and-trap gas chromatography.
Based on the data received from the eight provinces, the mean THM level was about 66 µg/L in drinking water samples from all systems. Some systems had average values in the 400 µg/L range, and some systems had maximum or peak values in the 800 µg/L range. From the eight provinces, 282 water systems (23% of sampled systems), representing a sampled population of 523 186 (3.4% of sampled population served), reported having mean THM levels greater than 100 µg/L, while 506 water systems (41%), serving a sampled population of 2 509 000 (16%), reported at least one instance of THM levels being greater than 100 µg/L (Water Quality Issues Sub-Group, 2003).

System mean chloroform levels for 1994–2000 were generally less than 50 µg/L, with some single maximum or peak values in the 400 µg/L range. From those suppliers who reported chloroform data, 290 water systems (26%), serving a sampled population of 1 130 000 (8%), reported mean chloroform levels greater than 75 µg/L, while 425 water systems (39%), serving 1 740 000 (12%) consumers, had a peak concentration greater than 75 µg/L in their drinking water during this period (Water Quality Issues Sub-Group, 2003).

Mean concentrations of both BDCM and DBCM in systems were generally less than 10 µg/L, although some averages were higher, and several locations reported one-time samples in excess of 200 µg/L. From those suppliers that reported BDCM data, 87 water systems (8% of reporting systems), representing a sampled population of 285 000 (2% of population served), reported having mean BDCM levels greater than 10 µg/L, while 192 water systems (18%), serving a sampled population of 1 165 000 (8%), reported at least one instance of BDCM levels being greater than 10 µg/L (Water Quality Issues Sub-Group, 2003).

Mean concentrations of bromoform were typically less than the detection limit, or approximately 0.5 µg/L, and individual values were less than 10 µg/L. In a few systems, however, average and maximum bromoform levels exceeded 30 µg/L over this period (Water Quality Issues Sub-Group, 2003).

Generally speaking, the smaller centres with less sophisticated treatment systems had higher THM levels in their drinking water. In this 1994–2000 national survey, it was found that where the population was unreported or less than 1000, 274 of systems had average THM levels greater than 75 µg/L, and 45 systems had average BDCM levels greater than 10 µg/L. Conversely, where the population was greater than 50 000 (and where more sophisticated treatment plants would be expected), there were only four systems whose average THM levels were greater than 75 µg/L, and only one system had an average BDCM level greater than 10 µg/L. For population centres with greater than 10 000 people, the 118 systems serving 11 036 000 people had an average system THM level of 37 µg/L — a value significantly lower than the average of 66 µg/L reported for all systems, regardless of size. For population centres with greater than 50 000 people, the 41 systems serving 9 439 000 people had an average THM level of about 27 µg/L (Water Quality Issues Sub-Group, 2003).

5.2 Multi-route exposure through drinking water

The importance of exposure to chloroform and BDCM via inhalation and dermal absorption from tap water during showering and bathing was evaluated. A modifying factor for each compound, in terms of litre-equivalents per day (Leq/day), was estimated by evaluating the relative contribution of inhalation and dermal exposures associated with showering and bathing.
Trihalomethanes (May 2006)

Krishnan (2003) determined Leq/day values for dermal and inhalation exposures of adults and children (6-, 10-, and 14-year-olds) during showering and bathing with tap water containing chloroform (5 µg/L) and BDCM (5 µg/L). The Leq/day values for a 10-minute shower and a 30-minute bath were calculated using the physiologically based pharmacokinetic (PBPK) model-generated data on the absorbed fraction (Corley et al., 1990, 2000; Haddad et al., 2001; Price et al., 2003). The “absorbed fraction” for the dermal and inhalation exposures took into consideration the dose that was absorbed following exposure as well as that portion that was exhaled in the following 24 hours.

Calculations done for chloroform and BDCM accounted for inter-chemical differences in water-to-air factor (based on differences in Henry’s law constants), fraction of dose absorbed during inhalation and dermal exposures, and skin permeability coefficient. Complete (100%) absorption of ingested chloroform and BDCM in drinking water was assumed for all subpopulations; this was supported by the available information on the extent of hepatic extraction of these THMs (Corley et al., 1990; DaSilva et al., 1999).

Leq/day values for the inhalation and dermal routes were higher for the 30-minute bath scenario than for the 10-minute shower for all subpopulations based on the longer exposure time. The highest total exposure values for drinking water were for adults in the 30-minute bath scenario: 4.11 Leq/day (1.5 L ingestion, 1.7 L inhalation, 0.91 L dermal) and 3.55 Leq/day (1.5 L ingestion, 0.67 L inhalation, 1.38 L dermal) for chloroform and BDCM, respectively. Both values are considered to be conservative, since most Canadians do not take a 30-minute bath on a daily basis. In the event that individuals spend more than 10 minutes in a shower or are exposed to chloroform or BDCM via other household activities or additional bathroom time, the above-calculated Leq/day values (which account for inhalation and dermal exposures from a 30-minute bath) are considered to be adequate for assessment.

5.3 Food and beverages

Data from the United States and Canada were sufficient to serve as a basis for estimating the minimum, midpoint, and maximum concentrations of chloroform in 131 of the 181 foods for which per capita daily intake rates (i.e., g/day) are available. The midpoint concentrations were greater than 100 µg/kg in 12 food items (i.e., butter, margarine, vegetable fats and oils, baby food cereal, pizza, marine fish, fresh fish, crackers, pancakes, veal, beef roast, and cheese). The highest concentrations of chloroform have frequently been measured in dairy products (Environment Canada and Health Canada, 2001).

Maximum concentrations of 2200 µg chloroform/kg and 3 µg BDCM/kg were detected in the fat of nine species of fish from six areas of the Norwegian coastline that were contaminated principally by discharges from pulp and paper plants, but also by agricultural runoff, chemical plants, and other industries. Bromoform and DBCM were detected in only one sample, at concentrations of 115 and 9 µg/kg, respectively (Ofstad et al., 1981). Neither chloroform nor BDCM was detected in composite samples of meat/fish/poultry (quantitation limits were 18 and 4.5 ng/g, respectively) or oil/fat (quantitation limits were 28 and 8.3 ng/g, respectively) from 39 different foods in the United States (Entz et al., 1982). In the composite sample of dairy foods, concentrations of chloroform and BDCM were 17 and 1.2 µg/L, respectively.

3 Although the calculations use assumptions of 5 µg/L for both chloroform and BDCM, the resulting Leq/day values are unlikely to change as long as actual concentrations remain in the µg/L range typically observed for THMs.
THM concentrations in six different cola and non-cola beverages (five samples of each) in New Jersey ranged from 3.2 to 44.8 µg/L (Abdel-Rahman, 1982). Concentrations of chloroform and BDCM in unspecified beverage composites from the United States averaged 32 and 1.0 µg/L, respectively (Wallace et al., 1984). Chloroform concentrations are approximately 10 times higher in cola soft drinks than in non-cola soft drinks, even for similar water sources (Abdel-Rahman, 1982; Entz et al., 1982; Wallace et al., 1984). This may be due to the method of extraction of the cola or the presence of caramel in these soft drinks. Chloroform was detected in 11 of 13 beverages sampled in Ottawa, at a maximum concentration of 14.8 µg/kg in a fruit drink (Environment Canada and Health Canada, 2001).

5.4 Consumer products

In the United States, emissions from approximately 5000 materials were determined, with a small number of these products emitting chloroform, usually in trace amounts. Emissions of chloroform were detected from the following materials (with median emission levels reported in parentheses): ink and pen (10.0 µg/g), miscellaneous housewares (4.85 µg/g), photographic equipment (2.5 µg/g), rubber (0.9 µg/g), electrical equipment (0.23 µg/g), lubricant (0.2 µg/g), adhesives (0.15 µg/g), fabric (0.1 µg/g), photographic film (0.1 µg/g), tape (0.05 µg/g), and foam (0.04 µg/g) (Environment Canada and Health Canada, 2001).

5.5 Swimming pools and hot tubs

The use of swimming pools results in inhalation and dermal exposure to THMs due mainly to the reaction between chlorine and organic matter. In indoor pool environments, concentrations of chloroform in plasma increase with the level of exertion of swimmers and are closely correlated with the chloroform concentrations in air and time spent swimming (Aggazzotti et al., 1990). In general, competitive swimmers are potentially exposed to higher levels of chloroform than are leisure swimmers due to higher breathing rates and longer durations of exposure (Health Canada, 1999).

The inhalation route appears to be significantly more important than the dermal route for swimmers. Levesque et al. (1994) determined that when swimmers (in indoor pools) are exposed to high concentrations of chloroform in the pool water and air, 78% and 22% of the body burden were due to inhalation and dermal uptake, respectively. Limited information suggests that users of hot tubs may have more significant dermal uptake than swimmers due to higher water temperatures (Wilson, 1995).

5.6 Estimates of total exposure to chloroform

Estimates of total chloroform exposure for the general population and the relative contribution of drinking water to total exposure were calculated by the World Health Organization (WHO, 2005). In this estimate, mean intake of chloroform from indoor air was estimated to be 0.3–1.1 µg/kg bw per day. The average intake of chloroform (inhalation and dermal absorption) during showering was 0.5 µg/kg bw per shower. Preliminary results from a study by Benoit et al. (1998), based on four volunteers, suggested that showering for 10 minutes with warm water that has been treated with a chlorinated disinfectant is equivalent to drinking 2.7 L of cold water per day from the same water supply, on an annual average. Dermal absorption accounted for an average of 30% of the total uptake. The estimated mean intake of
Trihalomethanes (May 2006)

chloroform from ingestion of drinking water for the general population, based on an average concentration of <20 µg/L, is less than 0.7 µg/kg bw per day. The estimated intake of chloroform from foodstuffs is approximately 1 µg/kg bw per day. Outdoor air exposure is estimated to be considerably less than exposure from other sources. The total estimated mean intake is approximately 2–3 µg/kg bw per day; for some individuals living in dwellings supplied with tap water containing relatively high concentrations of chloroform, estimates of total intake are up to 10 µg/kg bw per day (WHO, 2005).

As described above, swimming pools are an additional source of exposure to chloroform among swimmers. The daily dose of chloroform resulting from a 1-hour swim (65 µg/kg bw per day) in conditions found in public indoor swimming pools is much greater than any of the exposures estimated above (Levesque et al., 1994).

The Canadian Environmental Protection Act, 1999 (CEPA) Priority Substances List assessment report on chloroform (Environment Canada and Health Canada, 2001) developed deterministic estimates of chloroform exposure for six age groups based on data on concentrations of chloroform in outdoor and indoor air acquired in national surveys in Canada and on estimates of the concentrations of chloroform in foods in Canada and the United States. Estimates of intake in drinking water were based on monitoring data from the provinces and territories. Estimates of the average daily intake of chloroform by inhalation and dermal absorption during showering were also derived for teenagers, adults, and seniors.

Based on this report, the main sources of exposure to chloroform for the general population in Canada are inhalation of indoor air and ingestion of tap water. The contributions of outdoor air and food are considerably less than the contributions from indoor air and tap water (Environment Canada and Health Canada, 2001). Most of the chloroform in indoor air is present as a result of volatilization from drinking water (WHO, 2005). A more recent study using PBPK modelling (Krishnan 2003) found the highest chloroform exposure values among adults taking a 30-minute bath daily.

6.0 Analytical methods

The THMs can be determined by a number of different analytical techniques. The U.S. Environmental Protection Agency (EPA) has approved three methods (EPA Method 502.2; EPA Method 524.2 and EPA Method 551.1) for the analysis of THMs in drinking water. Method 502.2 uses purge and trap capillary column gas chromatography with photoionization and electrolytic conductivity detectors in series (P&T/GC-ECD); Method 524.2 determines THMs using capillary column gas chromatography/mass spectrometry (GC-MS) and Method 551.1 uses liquid-liquid extraction and gas chromatography with electron-capture detection (LLE/ECD) (U.S. EPA, 2005). Method detection limits (MDLs) for these methods are not listed.

Health Canada uses a purge and trap (P&T), liquid–liquid extraction (LLE), and direct aqueous injection in combination with a chromatographic system to analyze THMs. The chromatographic system will permit concurrent determination of all four THMs. The MDL by the P&T and LLE methods is approximately 0.1–0.2 µg/L (Health Canada, 1995).

Some of the techniques are known to give different values; for example, chloroform levels in water analysed by direct aqueous injection are usually higher than levels determined by
the purge-and-trap technique. The variation is attributed to the formation of chloroform from the breakdown of CDBP precursors in the hot injection port of the gas chromatograph used in the direct aqueous injection technique.

Health Canada studies on DBPs in drinking water used the LLE method from the EPA (Method 551.1), and adapted it to incorporate analysis by gas chromatography–electron capture detector (GC-ECD). Samples were also determined using the P&T technique followed by gas chromatography–mass spectrometry (ion trap) detector (GC-ITD).

The LLE approach also allows for the concurrent determination of other DBPs including chloral hydrate, di- and trichloropropanones, haloacetonitriles, and chloropicrin, which are not explicitly covered in this guideline document. The method was later modified to include the concurrent determination of cyanogen chloride (LeBel and Williams, 1996, 1997; LeBel and Benoit, 2000) and other halogenated acetaldehydes (Koudjonou and LeBel, 2003). An essential requirement of the method was the pH adjustment (pH 4.5) of the water samples at the time of field sampling to prevent further production of chloroform during storage of the sample between collection and analysis; the effect due to pH diminished with time (distance) in the distribution system (LeBel and Williams, 1995).

In order to ensure that the sample is representative of THM exposure, all reactions should be stopped at the time of sample collection. This is achieved by the addition of a preservative to quench the chlorine and by pH adjustment in the field to prevent the transformation of intermediate products. Data from recent Health Canada studies indicate that 1,1,1-trichloro-2-propanone (LeBel et al., 2002) and trihalogenated aldehydes (Koudjonou and LeBel, 2003) will degrade in water to their corresponding THMs at increased pH and temperature. However, they are stable in water at sampling/storage conditions (pH 4.5, 4°C).

Both the P&T/GC-ITD and LLE/GC-ECD techniques can be used for the determination of THMs in drinking water samples. For similarly treated samples (same pH and preservative), the results using both techniques are comparable, but the P&T technique gives slightly higher values of chloroform due to breakdown of some chlorinated intermediates (LeBel and Williams, 1995). As well, the P&T technique is not generally amenable to the analysis of the more hydrophilic DBP analytes targeted by the LLE approach. Therefore, the LLE approach is preferred for its versatility and reliability.

7.0 Treatment technology

THMs are formed in drinking water primarily as a result of chlorination of organic matter present in raw water supplies. It is therefore important, in assessing the risks associated with the ingestion of THMs in drinking water, to recognize the substantial benefits to health associated with disinfection by chlorination. The use of chlorine has virtually eliminated waterborne microbial diseases because of its ability to kill or inactivate essentially all enteric pathogenic microorganisms, including viruses and bacteria from the human intestinal tract. Chlorine is the most convenient and easily controlled disinfectant; it is a strong oxidant for which a residual can be maintained in the distribution system to prevent bacterial regrowth.

7.1 Municipal-scale

Existing treatment facilities and processes should be optimized to reduce the formation of THMs to levels as low as reasonably achievable without compromising disinfection.
At the municipal level, there are three approaches for reduction of THM concentrations in treated drinking water:
- removal of THM precursors prior to disinfection;
- modification of disinfection strategies and use of alternative disinfectants; and
- use of alternative water supply.

7.1.1 Removal of precursors prior to municipal disinfection

At the municipal level, control technologies for reduction of THM concentrations include optimization of precursor removal using conventional treatment, such as coagulation and sedimentation (Reid Crowther & Partners Ltd., 2000). In some situations, membrane filtration such as nanofiltration and ultrafiltration may be more suitable than conventional treatment, for treatment and economic reasons.

7.1.2 Alternative municipal disinfection strategies

Modification of chlorination practices, such as optimizing the chlorine dosage and changing the point of contact for chlorine, can help reduce THM concentrations in finished drinking water.

Alternative disinfectants to chlorine include chloramines, ozone and ultraviolet (UV) irradiation. Chloramines are a much weaker disinfectant than chlorine and are not recommended as primary disinfectants, especially where virus or parasite cyst contamination may be present (NAS, 1987). Moreover, although chloramines do not form significant levels of THMs, they are capable of inducing halogen substitution in organic compounds and thus may produce significant quantities of total organic halogen. Little is known about these oxidant residuals. The nature and toxicity of products formed from the organic base precursor fractions, particularly the organic chloramine portion of the chlorine residual, have not been characterized.

Ozone has been used as a primary disinfectant in water treatment plants in some parts of Canada and Europe. Ozone is an excellent disinfectant and does not form CDBPs; however, it must be used in combination with a secondary disinfectant to maintain a residual in the distribution system. Ozonation by-products include bromate, acids, and aldehydes, and chlorination of ozonated drinking water will result in increased levels of chloral hydrate as a result of the chlorination of acetaldehyde. Chloral hydrate may subsequently degrade to chloroform depending on pH, temperature, and maturity (e.g., age) of the water (LeBel and Benoit, 2000).

UV disinfection is a physical process that uses photochemical energy to effectively prevent cellular proteins and nucleic acids (i.e., DNA and RNA) from replicating. As a result, the microorganism cannot infect its host. UV disinfection does not induce any disinfectant residual in the water, requiring a secondary chemical disinfectant to maintain a residual in the distribution system. Since UV disinfection is dependent on light transmission to the microbes, the water quality characteristics affecting the UV transmittance need to be considered in the design of the system. UV irradiation under typical disinfection doses (less than 500 mJ/cm²) does not form significant levels of DBPs, nor does it affect the formation of CDBPs (especially THMs and HAAs) in the subsequent chlorination or chloramination processes (Reid Crowther & Partners Ltd., 2000).
The most effective approach for reduction of THMs in drinking water is the improvement of specific conventional water treatment processes and/or membrane filtration to remove organic compounds prior to disinfection, and the addition of special processes such as carbon adsorption and pre-oxidation. Initial removal of organic precursors precludes the need for reducing contact time, thus improving the efficiency of the disinfection process while still minimizing the formation of chlorinated organic by-products. The formation of THMs can be reduced with the use of granular activated carbon filtration. The level of reduction will be a function of the type and adsorbability of organic matter in the water as well as the process design criteria.

It is recommended that any change made to the treatment process, particularly when changing the disinfectant, be accompanied by close monitoring of lead levels in the distributed water. A change of disinfectant has been found to affect the levels of lead at the tap, for example in Washington, DC, where a change from chlorine to chloramines resulted in significantly increased levels of lead in the distributed drinking water. When chlorine, a powerful oxidant, is used as the disinfectant, lead dioxide scales formed in distribution system pipes have reached a dynamic equilibrium in the distribution system. In Washington, DC, switching from chlorine to chloramines decreased the oxidation-reduction potential of the distributed water and destabilized the lead dioxide scales, which resulted in increased lead leaching (Schock and Giani, 2004; Lytle and Schock, 2005). Subsequent laboratory experiments by Edwards and Dudi (2004) and Lytle and Schock (2005) confirmed that lead dioxide deposits could be readily formed and subsequently destabilized in weeks to months under realistic conditions of distribution system pH, oxidation-reduction potential and alkalinity.

### 7.2 Residential scale

Municipal treatment of drinking water is designed to reduce contaminants to levels at or below guideline value. As a result, the use of residential-scale treatment devices on municipally treated water is generally not necessary but primarily based on individual choice. For households that obtain their drinking water from a municipal system or a private well that chlorinates the water, treatment devices may be installed at the faucet (point-of-use) or where water enters the home (point-of-entry) to reduce THM levels. Certified point-of-use treatment devices are currently available for the reduction of THM levels.

Alternatively, for households which obtain their water from a private source, an ultraviolet (UV) disinfection system may be used to disinfect the water supply instead of chlorination. Certified UV disinfection systems are currently available for residential use.

Before a treatment device is installed, the water should be tested to determine general water chemistry. Pretreatment may be required to address water quality issues and to ensure that the treatment device will be effective. Consumers must refer to the manufacturer's literature to obtain information on the effectiveness of any treatment device being considered, as well as its operational and maintenance requirements and life span.

Health Canada does not recommend specific brands of drinking water treatment devices, but it strongly recommends that consumers look for a mark or label indicating that the device has been certified by an accredited certification body as meeting the appropriate NSF International (NSF)/American National Standards Institute (ANSI) standards. These standards have been designed to safeguard drinking water by helping to ensure the material safety and performance of products that come into contact with drinking water. Certification organizations provide
assurance that a product conforms to applicable standards and must be accredited by the Standards Council of Canada (SCC). In Canada, the following organizations have been accredited by the SCC to certify treatment devices and materials as meeting NSF/ANSI standards:

- Canadian Standards Association International (www.csa-international.org);
- NSF International (www.nsf.org);
- Water Quality Association (www.wqa.org);
- Underwriters Laboratories Inc. (www.ul.com);
- Quality Auditing Institute (www.qai.org); and
- International Association of Plumbing & Mechanical Officials (www.iapmo.org).

An up-to-date list of accredited certification organizations can be obtained from the SCC (www.scc.ca).

7.2.1 Filtration devices

Point-of-use and point-of-entry filtration systems, as well as some pour-through filters that use activated carbon filters, can be effective at removing chlorine and its by-products. It is important that the equipment be monitored and maintained according to the manufacturers’ recommendations, in particular the regular replacement of the filter media. The performance of filters intended for CDBP removal is dependent on a number of factors, including filter type, media type, CDBP group, flow rate, water quality and age of the filter. The use of filters in areas of high turbidity may cause filters to clog up very quickly without pretreatment.

For a drinking water treatment device to be certified to NSF/ANSI Standard 53 (Drinking Water Treatment Units — Health Effects), the device must reduce the concentration of THMs in water, using chloroform as a surrogate chemical, from an influent challenge concentration of 0.300 mg/L (300 µg/L) to less than 0.015 mg/L (15 µg/L), representing a chemical reduction of more than 95% (NSF International, 1999).

7.2.2 Alternative residential disinfection strategies

As with the municipal scale, UV irradiation is an alternative disinfection technology which can be installed for residential-scale treatment. UV disinfection is dependent on light transmission to the microbes through the raw water. For this reason, some pre-treatment of the raw water may be required to ensure the effectiveness of the UV disinfection.

The NSF/ANSI Standard 55 covers the certification requirements for UV disinfection systems. In particular, it addresses the Class A systems which are designed to inactivate and/or remove microorganisms, including bacteria, viruses, Cryptosporidium oocysts and Giardia cysts, from contaminated water. The Class A systems are not designed to treat wastewater or water contaminated with raw sewage, and should be installed in visually clear water (NSF International, 2002).

8.0 Kinetics and metabolism

8.1 Absorption

THMs are generally well absorbed, metabolized, and rapidly eliminated by mammals after oral or inhalation exposure (IPCS, 2000).
8.1.1 Chloroform
The absorption kinetics of chloroform following intragastric intubation are dependent upon the vehicle of delivery. Based on the calculated area under blood concentration–time curves (5 hours), uptake of chloroform following administration of 75 mg/kg bw by intragastric intubation in aqueous solution was 8.7 times greater than that for a similar dose administered in corn oil in paired Wistar rats (Withey et al., 1983).
Chloroform is readily absorbed through the skin of humans and animals, and significant dermal absorption of chloroform from water while showering has been demonstrated. Hydration of the skin appears to accelerate absorption of chloroform (Jo et al., 1990).

8.2 Distribution
8.2.1 Chloroform
Chloroform is distributed throughout the whole body, with levels being highest in the fat, blood, liver, kidneys, lungs, and nervous system. Distribution is dependent on exposure route; extrahepatic tissues receive a higher dose from inhaled or dermally absorbed chloroform than from ingested chloroform. Placental transfer of chloroform has been demonstrated in several animal species and humans. Unmetabolized chloroform is retained longer in fat than in any other tissue (WHO, 2005).

8.2.2 Brominated trihalomethanes
Brominated substitution would be expected to confer greater lipophilicity on the brominated THMs compared with chloroform, which would affect tissue solubility. Mink et al. (1986) found that the liver, stomach, and kidneys were the organs containing the highest BDCM levels. Mathews et al. (1990) found that repeated doses had no effect on the tissue distribution of BDCM in rats. Lilly et al. (1998) found slightly higher maximum concentrations of BDCM in the liver and kidneys after aqueous administration compared with corn oil delivery in male rats.

8.3 Metabolism
THMs are metabolized primarily to carbon dioxide and/or carbon monoxide.

8.3.1 Chloroform
Available data indicate that the toxicity of chloroform is attributable to its metabolites. Both oxidative and reductive pathways of chloroform metabolism have been identified, although in vivo data are limited. The metabolism of chloroform proceeds through a cytochrome P450-dependent activation step, regardless of whether oxidative or reductive reactions are occurring. The balance between oxidative and reductive pathways depends on species, tissue, dose, and oxygen tension. Tissues with chloroform-metabolizing ability include liver, kidney cortex, and tracheal, bronchial, olfactory, oesophageal, laryngeal, tongue, gingival, cheek, nasopharyngeal, pharyngeal, and soft palate mucosa. Of these, the liver is the most active, followed by the nose and kidney. The rate of biotransformation to carbon dioxide is higher in rodent (hamster, mouse, rat) hepatic and renal microsomes than in human hepatic and renal microsomes. Strain- and sex-related differences in sensitivity of mice to nephrotoxicity are correlated with the ability of the kidney to metabolize chloroform. Chloroform is biotransformed more rapidly in mouse than in rat renal microsomes (Environment Canada and Health Canada, 2001).
The oxidative biotransformation of chloroform is catalysed by cytochrome P450 to produce trichloromethanol. Loss of hydrogen chloride from trichloromethanol produces phosgene as a reactive intermediate. Phosgene may be detoxified by reaction with water to produce carbon dioxide or by reaction with thiols, including glutathione and cysteine, to produce adducts. Carbon dioxide is the major metabolite of chloroform generated by the oxidative pathway \textit{in vivo}. Both products of oxidative activation, phosgene and hydrochloric acid, can cause tissue damage. Phosgene reacting with tissue proteins is associated with cell damage and death. Increased covalent binding of chloroform metabolites in the liver occurs when glutathione is depleted (Environment Canada and Health Canada, 2001). Phosgene can bind covalently to cellular nucleophiles, but little binding of chloroform metabolites to DNA is observed. Chloroform also undergoes cytochrome P450-catalysed reductive biotransformation to produce the dichloromethyl radical (with and without phenobarbital induction), which becomes covalently bound to tissue lipids.

Secondary metabolic pathways are reductive dehalogenation via CYP2B1/2/2E1 (leading to free radical generation) and glutathione conjugation via theta-class glutathione-S-transferase T1-1 (GSTT1-1), which generates mutagenic intermediates. Glutathione-S-transferase-mediated conjugation of chloroform to glutathione can occur only at extremely high chloroform concentrations or doses (IPCS, 2000). Reduced glutathione is capable of scavenging essentially all chloroform metabolites produced in incubations with mouse liver microsomes when chloroform concentrations are not too high (Environment Canada and Health Canada, 2001). Although the findings should be interpreted with caution, Delic et al. (2000) used PBPK modelling to estimate that humans would need to be exposed to 645 mg/m$^3$ (130 ppm) by inhalation to attain levels of active metabolites associated with a concentration of 50 mg/m$^3$ (10 ppm) in mice. Based on comparison of the formation of reactive metabolites as measured by binding of radioactivity from $[^{14}C]CHCl_3$ (0–10 mmol) in rat and human liver microsomes, it was concluded that the metabolism in these species is similar, although less efficient in humans (Cresteil et al., 1979).

In eight human volunteers ingesting gelatin capsules containing chloroform (500 mg in olive oil), a maximum of 68.3% and 50.6% of the dose was found in the expired air as chloroform and carbon dioxide, respectively, 8 hours post-administration (Fry et al., 1972; NAS, 1987). There was an inverse relationship between the adipose tissue content of the body and pulmonary elimination of chloroform (Fry et al., 1972).

\subsection*{8.3.2 Brominated trihalomethanes}
BDCM is metabolized to phosgene, while DBCM and bromoform are metabolized to brominated analogues of phosgene. The rate of metabolism of these compounds to carbon monoxide both \textit{in vivo} and \textit{in vitro} generally follows the halide order, namely, bromoform $>>$ DBCM $>$ BDCM $>$ chloroform. The International Programme on Chemical Safety (IPCS, 2000) postulated that the brominated THMs may be more rapidly and more extensively metabolized than their chlorinated counterparts. Although this may be true for BDCM, support for this statement, as it pertains to DBCM or bromoform, is difficult to determine from the limited currently available literature. The majority of the comparative metabolism studies...
conducted to date are limited to chloroform or BDCM. Nonetheless, it would appear that the toxicity of BDCM and likely other brominated THMs is mediated through a bioactivation pathway (IPCS, 2000).

Thornton-Manning et al. (1994) concluded that there were clear interspecies differences in metabolism of BDCM, which may explain the greater sensitivity of rats, relative to mice, to the hepatotoxicity of orally administered BDCM. Within 8 hours following intragastric administration of 150 mg/kg bw (rats) or 100 mg/kg bw (mice) in corn oil, 4–18% and 40–81% of total radiolabelled THMs were eliminated as carbon dioxide through the lungs in expired air in rats and mice, respectively. In the same experiment, 41–67% and 5–26% of the parent compound were eliminated unchanged in rats and mice, respectively. Less than 10% of the total radiolabel for each of the chemicals was detected in the urine of both species 36–48 hours post-exposure; the proportion excreted in the urine for both species was greatest for chloroform, followed by, in descending order, bromoform, BDCM, and DBCM. The authors considered the metabolism of these compounds in the mouse to be 4- to 9-fold greater than that in the rat; however, it should be noted that the administered doses were high and that metabolism in both species is more complete following administration of lower, more relevant doses.

Pegram et al. (1997) provided evidence that the mutagenic metabolic pathway for brominated THMs is mediated by GSTT1-1 conjugation and that the mutagenic pathway of chloroform is not. These findings suggest that chlorinated and brominated THMs may be activated by different mechanisms. DeMarini et al. (1997) examined the ability of GSTT1-1 to mediate the mutagenicity of various THMs, reported nucleotide transitions (GC → AT) mediated by glutathione-S-transferase in *Salmonella*, and ranked the THMs according to relative mutagenic potency as follows: bromoform = DBCM > BDCM. GSTT1-1 conjugation of BDCM was confirmed by Ross and Pegram (2003), who characterized the reaction kinetics of the conjugation of BDCM with glutathione in mouse, rat, and human hepatic cytosols. Reactive glutathione conjugates produced may result in the formation of DNA adducts. Furthermore, these reactive intermediates produced by glutathione conjugation of BDCM are more mutagenic/genotoxic than intermediates produced from dichloromethane.

Allis et al. (2001) and Lilly et al. (1997) investigated the metabolism of BDCM following inhalation exposure in male rats. The findings suggest that CYP2E1 is the dominant enzyme involved in the metabolism of inhaled BDCM in rats (GlobalTox, 2002). Lilly et al. (1998) also found that more of the parent BDCM compound was eliminated unmetabolized via exhaled breath after aqueous dosing than after corn oil gavage.

### 8.3.3 Mixtures of THMs

A PBPK model was developed by DaSilva et al. (2000), who found that exposures to binary mixtures of chloroform and BDCM, DBCM, or bromoform would likely result in significant increases in the levels of unmetabolized chloroform in the blood, relative to chloroform administered alone. This study also demonstrated that clearance of THMs may be impacted by toxicokinetic interactions between THMs. Bromoform and DBCM appear to persist in blood and tissues for longer periods of time when co-administered with chloroform than when given alone (GlobalTox, 2002).
8.4 Excretion

8.4.1 Chloroform

In animals and humans exposed to chloroform, carbon dioxide and unchanged chloroform are rapidly eliminated in the expired air. The fraction of the dose eliminated as carbon dioxide varies with the dose and the species (IPCS, 2000).

8.4.2 Bromodichloromethane

Mink et al. (1986) estimated BDCM half-lives at 1.5 and 2.5 hours in the rat and mouse, respectively. Mathews et al. (1990) found that urinary and faecal elimination were low at all dose levels in male rats. Elimination kinetics of BDCM have been studied in humans who had been swimming in chlorinated pools; BDCM half-lives of 0.45–0.63 minutes for blood were estimated using breath elimination data (Lindstrom et al., 1997; Pleil and Lindstrom, 1997).

8.5 PBPK models

PBPK modelling is a technique that may inform and improve toxicological assessments, through a better assessment of the magnitude of the uncertainty factors applied in current risk assessment by informing on issues relating to extrapolation between and within species (Delic et al., 2000).

8.5.1 Chloroform

The 2001 CEPA assessment report on chloroform (Environment Canada and Health Canada, 2001) indicated that the exposure–response relationship for exposure to chloroform associated with cancer and rates of formation of reactive metabolites in the target tissue is upheld by evidence supporting the following assumptions inherent in the PBPK modelling:

1. In both experimental animals and humans, metabolism of chloroform by CYP2E1 is responsible for production of the critical reactive metabolite, phosgene.
2. The ability to generate phosgene and phosgene hydrolysis products determines which tissue regions in the liver and kidney are sensitive to the cytotoxicity of chloroform.
3. This dose–effect relationship is consistent within a tissue, across gender, and across route of administration, and it may also be consistent across species.

The CEPA report presented a PBPK model that was a “hybrid” animal model of the International Life Sciences Institute Expert Panel, which was revised for their assessment and developed to permit its extension to humans (ILSI, 1997; ICF Kaiser, 1999). For this assessment, maximum rate of metabolism per unit kidney cortex volume (VRAMCOR) and mean rate of metabolism per unit kidney cortex volume during each dose interval (VMRATEK) were considered (Environment Canada and Health Canada, 2001).

a) Neoplastic assessment: The results of the exposure–response neoplastic assessment presented were for the combined incidence of renal adenomas and adenocarcinomas in Jorgenson et al. (1985). The VMRATEK associated with a 5% increase in tumour risk (TC05) in humans estimated on the basis of the PBPK model is 3.9 mg/L per hour (95% confidence limit = 2.5, chi-square = 0.04, degrees of freedom = 1, P-value = 0.84). This dose would result from continuous lifetime exposure to chloroform at 3247 mg/L in water or 149 mg/m³ (30 ppm) in air. Respective lower 95% confidence limits for these values are 2363 mg/L and 74 mg/m³ (15 ppm).
Although the data on dose–response were less robust than those for the cancer bioassay, for comparison, a benchmark dose was developed for histological lesions in the kidney in the re-analysis of a subset of the slides from the Jorgenson et al. (1985) bioassay. The VMRATEK in humans associated with a 5% increase in histological lesions characteristic of cytotoxicity is 1.7 mg/L per hour (95% lower confidence limit = 1.4, chi-square = 3.9, degrees of freedom = 2, P-value = 0.14). This dose rate would result from continuous lifetime exposure to 1477 mg/L in water or 33.8 mg/m\(^3\) (6.8 ppm) in air (Environment Canada and Health Canada, 2001).

b) **Non-neoplastic assessment**: Short-term exposure by inhalation resulted in cellular proliferation in nasal passages in rats and mice at concentrations as low as 9.9 mg/m\(^3\) (2 ppm), with ossifications being observed at slightly higher concentrations following long-term exposure. Moderate hepatic changes were observed in short-term studies in mice at 50 mg/m\(^3\) (10 ppm); following both short- and long-term exposure to 124–149 mg/m\(^3\) (25–30 ppm), there were multiple adverse effects in the kidney and liver in both rats and mice in several studies. Following ingestion in drinking water, regenerative proliferation after short-term exposure of mice to doses as low as 17 mg/kg bw has been observed. Following bolus dosing, increases in proliferation in the liver of rats have been observed after short-term exposure of rats at 10 mg/kg bw per day, and fatty cysts have been observed in the liver of dogs given 15 mg/kg bw per day.

As one of the lowest oral dose levels at which effects on liver and kidney have been observed was in dogs in a study by Heywood et al. (1979), a PBPK model in dogs was developed, keeping in mind that effects on the liver of rodents have also been observed in a similar dose range. Two dose metrics were investigated in exposure–response: the mean rate of metabolism per unit centrilobular region of the liver and the average concentration of chloroform in the non-metabolizing centrilobular region of the liver. The two dose metrics were selected in order to evaluate the possibility of the fatty cyst formation in the dogs being the result of the solvent effects of chloroform or effects of a reactive metabolite. Results of a model fitting supported the assumption that a metabolite, rather than chloroform itself, was responsible for the observed effects. This means that the effect of chloroform on the liver will vary depending on the rate of metabolism. The mean rate of metabolism per unit centrilobular region of the liver in humans associated with a 5% increase in fatty cysts estimated on the basis of the PBPK model is 3.8 mg/L per hour (95% lower confidence limit = 1.3, chi-square = 0.00, degrees of freedom = 1, P-value = 1.00). This dose rate would come from continuous lifetime exposure to 37 mg/L in water or 9.9 mg/m\(^3\) (2 ppm) in air. Both levels should be interpreted with caution, because they are not derived using a complete risk assessment approach. They represent only an estimate of levels of exposure in drinking water and/or in air to which humans would need to be exposed over a lifetime in order to attain the selected effect level (5% increase of fatty cysts in the liver).

The 2001 CEPA assessment report concluded, based on the above PBPK models, that the exposure of the general population is considerably less than the level to which it is believed a person may be exposed daily over a lifetime without deleterious effect. Underestimates in exposure due to use of hot rather than cold water and increased chloroform levels in the distribution system compared with the water treatment plant were noted (Environment Canada and Health Canada, 2001).
8.5.2 Bromodichloromethane

A PBPK model has been developed to describe the absorption, distribution, tissue uptake and dosimetry, metabolism, and elimination of BDCM in rats. The metabolism model, derived from inhalation exposure data, was subsequently linked to a multicompartment gastrointestinal tract submodel. This model accurately predicted tissue dosimetry and plasma bromide ion concentrations following oral exposure to BDCM and can be utilized in estimating rates of formation of reactive intermediates in target tissues (Lilly et al., 1997, 1998).

9.0 Effects in humans

9.1 Cancer epidemiology

Epidemiological studies conducted prior to 1993 that explored associations between and adverse health outcomes often had limitations, particularly in the area of exposure measurement. In the case–control epidemiological studies conducted prior to 1993, associations were found between ingestion of chlorinated drinking water and the incidences of colon cancer for those aged 60 years or more (Cragle et al., 1985) and bladder cancer among non-smokers (Cantor et al., 1985, 1987). In the investigation by Cantor et al. (1985), which involved 1244 cases and 2500 control subjects who had never been exposed in high-risk occupations for bladder cancer and for which detailed information on geographic mobility, water source (non-chlorinated ground source or chlorinated surface source for 50% of their lifetime), and potential confounders was collected, there was a positive association between bladder cancer risk, level of tap water ingestion, and duration of exposure, predominantly among study subjects with long-term residence in communities with chlorinated surface water (NAS, 1987). Among non-smokers, there was an association between water intake and relative risk, and the odds ratio for those over 60 with more than median surface water intake compared with lifelong groundwater consumers was 2.3.

There has been an ongoing effort since 1993 to improve the design of these epidemiological studies in order to more clearly identify both the possible agents of concern in chlorinated drinking water and the associated adverse health effects. More recent analytical epidemiological investigations of bladder cancer have been conducted in Colorado (McGeehin et al., 1993), Ontario (King and Marrett, 1996), and Iowa (Cantor et al., 1996). Data reported thus far from a study in Iowa indicate that risk of bladder cancer is not associated with estimates of past exposure to chlorination by-products, except among men who had ever smoked, for whom bladder cancer risk increased with duration of exposure after control for cigarette smoking. No increased relative risk of bladder cancer was associated with exposure to chlorinated municipal surface water supplies, to chloroform, or to other THM species in a cohort of women, but the follow-up period of 8 years was very short, resulting in few cases for study. In Ontario, King and Marrett (1996) found an increased bladder cancer risk with increasing duration of exposure and THM levels. The association was statistically significant and of higher magnitude only after 35 or more years of exposure. The authors use a concept of THM-years to express the cumulative exposure to THM, which incorporates both levels of exposure to THMs and the period of exposure and is measured in µg/L-years. The bladder cancer incidence was about 40% higher among persons exposed to greater than 1956 µg/L-years of THMs in water compared with those exposed to less than 584 µg/L-years. Although it is not possible to conclude on the basis of
available data that this association is causal, observation of associations in well-conducted studies where exposures were greatest cannot be easily dismissed. In addition, it is not possible to attribute these excesses to chloroform *per se*, although it is generally the DBP present at highest concentration in drinking water (IPCS, 2000). In 2002, an expert panel convened by Health Canada to identify critical endpoints for assessment of health risks related to THMs in drinking water also agreed that THMs are used in epidemiological studies as a surrogate for exposure to CBDPs more generally, and the complexity of CDBP mixtures in drinking water makes the assignment of causation to any single component or class of components extremely difficult (Health Canada, 2003a).

In 2002, Health Canada commissioned a review of the non-bladder cancer epidemiology of THMs in drinking water (SENES Consultants Ltd., 2002). The studies reviewed focussed on colon, rectal, pancreatic, kidney, brain, and haematological/lymphoreticular cancer sites. There were only a few studies with significant odds ratios for colon, rectal, brain and pancreatic cancer; studies were not significant for kidney and the blood-related cancers.

For colon cancer, there were two studies showing a statistically increased risk of colon cancer with exposure to chlorinated drinking water. King et al. (2000a) showed a significant association only for the male cohort, whereas Doyle et al. (1997) showed one only in females, as only females were considered. The results of the King et al. (2000a) study suggest that there may be different risk factor profiles for the different sexes insofar as there was no significant risk for females. However, the Iowa cohort (Doyle et al., 1997) indicates that this may not be the case.

Results from the studies involving rectal cancer were inconclusive. Of the studies examined, the only study showing significance was a population-based case–control study by Hildesheim et al. (1998). Hildesheim et al. (1998) and Doyle et al. (1997) both used the Iowa population and cancer registry for their studies. Their methodologies differed, in that Hildesheim et al. (1998) used a case–control design, examining rectal and colon cancers for both men and women, while Doyle et al. (1997) used a cohort design, examining only women in the population, prospectively, for colon and rectal cancers. Doyle et al. (1997) found an association only for colon cancer, while Hildesheim et al. (1998) found one for rectal cancer.

The only recent study involving the association between brain cancer and exposure to THMs indicated that such an association exists (Cantor et al., 1999). This study involved the same Iowa-based cohort used by Hildesheim et al. (1998) and Doyle et al. (1997).

In summary, even though recent studies suggest that some association exists between colon, rectal, and brain cancer and exposure to DBPs in drinking water, the data presented in the studies are not sufficient to reliably confirm a dose–response or causal relationship (SENES Consultants Ltd., 2002).

The only study that found any significant relationship between treated water and pancreatic cancer was an ecological study by Koivusalo et al. (1995) involving 56 communities in 1950 in Finland. The inherent limitations and uncertainties associated with ecological studies make it difficult to acknowledge the outcome of this study and raise concerns about confidence in the results.

Several studies have attempted to estimate exposures to THMs or chloroform and the other THM species, but the studies did not consider exposures to other DBPs or other water contaminants, which may differ between surface water and groundwater sources. Because inadequate attention has been paid to assessing exposure to water contaminants in

---

*Guidelines for Canadian Drinking Water Quality: Guideline Technical Document*
epidemiological studies, it is not possible to properly evaluate the increased relative risks that have been reported. Specific risks may be due to other DBPs, mixtures of by-products, or other water contaminants, or they may be due to other factors for which chlorinated drinking water or THMs may serve as a surrogate (WHO, 1998; IPCS, 2000).

9.2 Reproductive epidemiology

Epidemiological studies have raised concerns regarding the potential effects of exposure to DBPs in drinking water and reproductive and developmental outcomes, supported in part by the findings that some DBPs cause reproductive and developmental toxicity in laboratory animals, albeit at doses much higher than those encountered by humans. In 1997, both Health Canada and the U.S. EPA held scientific panel workshops that concluded that the evidence at the time was insufficient to establish a causal relationship between chlorinated water or THMs and adverse pregnancy outcomes (Mills et al., 1998; IPCS, 2000).

Reif et al. (2000) conducted a critical review of the most recent epidemiological evidence. This review examined studies that used either 1) qualitative exposure assessment, which examined associations between source of water supply or method of disinfection and risk of adverse reproductive outcome or 2) quantitative exposure assessment, relying predominantly on reported concentrations of THMs in drinking water supplies. Reif et al.’s (2000) conclusions were as follows:

a) Effects on fetal growth: The epidemiological evidence for an association between THMs and effects on fetal growth is inconsistent. Weak but statistically significant associations (odds ratios: 1.2–2.6) with birth weight, low birth weight, and intrauterine growth retardation were described in epidemiological studies at concentrations of ≥61 µg THMs/L (Gallagher et al., 1998), >80 µg THMs/L (Bove et al., 1992), and >100 µg THMs/L (Bove et al., 1995). Increases in risk for intrauterine growth retardation were also reported at concentrations of chloroform and BDCM ≥10 µg/L, although the latter was not statistically significant (Kramer et al., 1992). Conversely, two studies (Savitz et al., 1995; Dodds et al., 1999) were unable to demonstrate a statistically significant association with any of these related outcomes. Among these studies, all adjusted for an indicator of socioeconomic status and for race, or restricted the analysis to caucasians. Smoking was controlled for in all but one (Bove et al., 1995) study. The two largest studies, each with good statistical power, reached different conclusions despite relative similarity in exposure assessment and other methods (Bove et al., 1995; Dodds et al., 1999).

In a hospital-based study in Italy, Kanitz et al. (1996) reported lower mean birth weights among mothers older than 30 years of age consuming chlorinated water. Kallen and Robert (2000) also reported an effect of chlorine-treated systems on somatic parameters of body length and head circumference, as well as an association with low birth weight and preterm delivery. However, Jaakkola et al. (1999) reported no association between chlorinated water use and measures of fetal growth or prematurity. Yang et al. (2000) found no evidence of an association between low birth weight and chlorination in Taiwan, but municipalities using chlorination had a significantly higher rate of preterm delivery.
b) Effects on fetal viability: Epidemiological evidence is inconsistent in associating DBPs with an increased risk of spontaneous abortion and stillbirth. Although these endpoints were grouped together in the Reif et al. (2000) report, their mechanisms of induction may differ. Increased rates of spontaneous abortion were reported in a cohort study by Waller et al. (1998) in California with heavy consumption of water (five or more glasses of cold tap water per day) containing $\geq 75 \mu g/L$ of THMs. When specific THMs were considered, only heavy consumption of water containing BDCM ($\geq 18 \mu g/L$) was associated with a risk of miscarriage (IPCS, 2000). An increased risk of spontaneous abortion associated with DBP formation is supported by findings from Aschengrau et al. (1989), who reported a doubling in risk for the consumption of surface water, compared with groundwater and mixed water systems. Savitz et al. (1995) found a statistically significant relationship with increasing concentration of THMs and with the highest sextile of exposure, but there was no relationship with ingested dose or with water source.

An increased risk of stillbirth was reported for Nova Scotia women exposed to water containing more than 100 $\mu g$ THMs/L (Dodds et al., 1999). In further analyses of these data, King et al. (2000b) found dose-dependent increases in adjusted risk for stillbirth with exposure to THMs, chloroform, and BDCM. Exposure to BDCM at levels $\geq 20 \mu g/L$ was associated with a doubling in risk. In New Jersey, Bove et al. (1992, 1995) found little evidence for an association with THMs at 80 $\mu g/L$, but did report a weak association between stillbirth and consumption of drinking water from surface water systems. Aschengrau et al. (1993) found an association between stillbirth and the use of a chlorinated versus chloraminated surface water supply.

c) Effects on risk for fetal malformations: Relatively strong associations of several types of congenital anomalies with THMs were described by Bove et al. (1992, 1995). The highest risks were found for central nervous system, oral cleft, and major cardiac defects at THM concentrations above 80 or 100 $\mu g/L$. Other studies of neural tube defects (Dodds et al., 1999; Klotz and Pyrch, 1999) and cardiac anomalies (Shaw et al., 1991; Dodds et al., 1999) found lower risks or no evidence of an association with THMs. The literature to date presents an inconsistent pattern of association with congenital anomalies collectively and a lack of consistency with specific anomalies across the relatively few studies that have explored these outcomes.

A 2005 study published by the Awwa Research Foundation was conducted to address the hypothesis that exposure to CDBPs causes pregnancy loss (Savitz et al., 2005). To reflect a range of CDBP concentrations and speciation typical of those found across the United States, three study sites were selected which contained either very low levels of all CDBPs, moderate levels of all CDBPs, or combined low levels of chlorinated species and moderate levels of brominated species. Women in each of these areas who were planning a pregnancy or who were pregnant at less than 12 weeks gestation were recruited into the study. In contrast to the Waller et al. (1998) study, the Savitz et al. (2005) study found women who drank 5 or more glasses per day of tap water with $>75 \mu g/L$ THMs had the same risk of pregnancy loss (an odds ratio of 1.0) as all other women, indicating no association between exposure and pregnancy loss. They did find
some indication that BDCM and DBCM were associated with an increased risk of pregnancy loss. However, the results were generally not supportive of an association between pregnancy loss and exposure to CDBPs.

10.0 Effects on experimental animals and in vitro

10.1 Acute toxicity

At acutely toxic doses, chloroform causes central nervous system depression and cardiac effects. In rats, the clinical signs of acute toxicity for all of the THMs are similar and include piloerection, sedation, flaccid muscle tone, ataxia, and prostration. LD\textsubscript{50}s for chloroform, BDCM, DBCM, and bromoform were 908, 916, 1186, and 1388 mg/kg bw, respectively, in male rats and 1117, 969, 848, and 1147 mg/kg bw, respectively, in female rats. In surviving animals, there were a variety of effects, including reduced food intake, growth retardation, increased liver and kidney weights, haematological and biochemical effects, and histological changes in the liver and kidney (Chu et al., 1980). Keegan et al. (1998) characterized the no-observed-adverse-effect level (NOAEL) and lowest-observed-adverse-effect level (LOAEL) for acute hepatotoxicity in F344 rats for both chloroform and BDCM delivered in an aqueous vehicle. For both chloroform and BDCM, the oral NOAEL was 0.25 mmol/kg bw, and a LOAEL of 0.5 mmol/kg bw was determined. Assessment at later time points indicated that liver damage caused by BDCM is more persistent than that caused by chloroform.

Based on data on chloroform, and limited data on DBCM, BDCM and bromoform, the literature suggests that rats are more sensitive than mice to acute effects of THMs. The critical effects associated with acute oral exposure in animals, irrespective of the target organ, are cellular degeneration, damage, and/or necrosis (GlobalTox, 2002).

10.2 Subchronic toxicity

10.2.1 Trihalomethanes

The liver and thyroid, rather than the liver and kidney, were the organs most affected following administration of each of the THMs in a subchronic study (Chu et al., 1982a,b). Groups of 20 male and female SD rats ingested drinking water containing chloroform, BDCM, DBCM, or bromoform at concentrations of 5, 50, 500, or 2500 mg/L for 90 days; estimated doses were 0.11–0.17, 1.2–1.6, 8.9–14, and 29–55 mg/day per rat, respectively. Ten animals in each group were killed at the end of exposure, and the remaining animals were sacrificed 90 days later.

The growth rate was suppressed in animals administered chloroform and BDCM at 2500 mg/L at the end of exposure but not following the 90-day recovery period. Food consumption was also depressed during both exposure and recovery periods in groups receiving chloroform, DBCM, or BDCM at 2500 mg/L. Food consumption in males was depressed during exposure to 2500 mg bromoform/L but was normal at the end of the recovery period. Lymphocyte counts were decreased at the end of the recovery period in groups receiving 500 mg chloroform/L, 2500 mg DBCM/L, or 2500 mg bromoform/L. Mild, reversible histological changes in the liver and thyroid of exposed groups were reported, with the hepatotoxicity being greatest for bromoform, followed by, in descending order, BDCM, DBCM, and chloroform; however, the incidence of the lesions was not dose-related, although the frequency of more
severe changes was greater in higher dose groups (statistical significance not reported). As the histological effects were mild and reversible and the haematological effects observed in chloroform-exposed animals were not dose-related, the NOAEL for all of the THMs in this study is considered to be 500 mg/L; the LOAEL is considered to be 2500 mg/L.

10.2.2 Chloroform

In a 90-day study in which CD-1 male and female mice (7–12 animals of each sex per treatment group) received 50, 125, or 250 mg chloroform/kg bw per day by intubation in Emulphor deionized water, there was a dose-related increase in liver weights and a decrease in hepatic microsomal activities in high-dose males and in females at all dose levels (Munson et al., 1982). Hexobarbital sleeping times were also increased in mid- and high-dose females. Blood glucose was increased in the high-dose groups of both sexes, and humoral immunity was decreased in high-dose males and mid- and high-dose females. Cellular immunity was decreased in high-dose females. The authors also reported slight histopathological changes in the kidney and liver of both sexes but did not provide information on the prevalence, severity, or dose–response relationship. The LOAEL for female mice in this study is considered to be 50 mg/kg bw; for males, the LOAEL is 250 mg/kg bw and the NOAEL is 125 mg/kg bw. The absence in this investigation of an increase in serum glutamic–pyruvic transaminase and serum glutamic–oxaloacetic transaminase observed in the high-dose groups in a 14-day study with a similar dosing regimen by the same investigators led the authors to conclude that some tolerance to the hepatotoxic action of chloroform may develop following long-term exposure.

The importance of the vehicle of administration in the toxicity of chloroform was demonstrated in a study in which groups of 80 male and female B6C3F1 mice were exposed to 60, 130, or 270 mg/kg bw per day by gavage in corn oil or a 2% Emulphor suspension for 90 days. Chloroform caused more marked hepatotoxic effects when administered in corn oil than in aqueous suspension, as determined by body and organ weights, serum chemistry, and histopathological examination (Bull et al., 1986).

Chloroform was administered by corn oil gavage to five male B6C3F1 mice per dose group at doses of 0, 34, 90, 138, or 277 mg/kg bw for 4 days or 3 weeks (5 days per week). Mild degenerative changes in centrilobular hepatocytes were noted in mice given 34 or 90 mg/kg bw per day after 4 days of treatment, but these effects were absent at 3 weeks. At 138 and 277 mg/kg bw per day, centrilobular necrosis was observed at 4 days and with increased severity at 3 weeks. Hepatic cell proliferation was increased in a dose-dependent manner at all chloroform doses after 4 days, but only in the 277 mg/kg bw group at 3 weeks. Renal tubular necrosis was observed in all treated groups after 4 days, while 3 weeks of exposure produced severe nephropathy at the highest dose and regenerating tubules at the lower doses. The nuclear labelling index was increased in the proximal tubules at all doses after 4 days of treatment, but was elevated only in the two highest dose groups after 3 weeks (Larson et al., 1994a).

In a similar study, five female B6C3F1 mice per dose group were administered chloroform dissolved in corn oil by gavage at doses of 0, 3, 10, 34, 238, or 477 mg/kg bw per day for 4 days or 3 weeks (5 days per week). Dose-dependent changes included centrilobular hepatic necrosis and markedly elevated labelling index in mice given 238 or 477 mg/kg bw per day. The NOAEL for histopathological changes (cytolethality and regenerative hyperplasia) was 10 mg/kg bw per day, and for induced cell proliferation, 34 mg/kg bw per day. In the same
study, 14 female B6C3F1 mice per dose group were continuously exposed to chloroform in the drinking water at concentrations of 0, 60, 200, 400, 900, or 1800 mg/L for 4 days or 3 weeks. There was no increase in the hepatic labelling index after either 4 days or 3 weeks in any of the dose groups, nor were any microscopic alterations observed in the liver, even though the cumulative daily amount of chloroform ingested in the high-dose group was 329 mg/kg bw per day. The authors suggested that mice provided with chloroform in the drinking water ad libitum received the dose over the entire day with much smaller peak tissue levels than when the compound was administered as a bolus dose (Larson et al., 1994b).

Five female F344 rats per dose group were given chloroform by corn oil gavage at doses of 0, 34, 100, 200, or 400 mg/kg bw per day for 4 consecutive days or 5 days per week for 3 weeks (Larson et al., 1995b). In the liver, mild degenerative centrilobular changes and dose-dependent increases in hepatocyte proliferation were noted at doses of 100, 200, and 400 mg/kg bw per day. At 200 and 400 mg/kg bw per day, degeneration and necrosis of the renal cortical proximal tubules were observed. Increased regenerative proliferation of epithelial cells lining proximal tubules was seen at doses of 100 mg/kg bw per day or more. Lesions of the olfactory mucosa lining the ethmoid region of the nose (new bone formation, periosteal hypercellularity, and increased cell replication) were seen at all doses, including the lowest dose of 34 mg/kg bw per day.

Larson et al. (1995a) also administered chloroform to 12 male F344 rats per dose group by corn oil gavage (0, 10, 34, 90, or 180 mg/kg bw per day) or in the drinking water (0, 60, 200, 400, 900, or 1800 mg/L) for 4 days or 3 weeks. Gavage of 90 or 180 mg/kg bw per day for 4 days induced mild to moderate degeneration of renal proximal tubules and centrilobular hepatocyte changes that were no longer present after 3 weeks. Increased cell proliferation in the kidney was noted only at the highest gavage dose after 4 days. The labelling index was elevated in the livers of the high-dose group at both time points. With drinking water administration, rats consuming the water containing 1800 mg/L were dosed at a rate of 106 mg/kg bw per day, but no increase in renal or hepatic cell proliferation was observed at this or any lower dose.

The cardiotoxicity of chloroform was examined in male Wistar rats given daily doses of 37 mg/kg bw (0.31 mmol/kg) by gavage in olive oil for 4 weeks. Chloroform caused arrhythmogenic and negative chronotropic and dromotropic effects as well as extension of the atrioventricular conduction time and depressed myocardial contractility (Muller et al., 1997).

In an inhalation study, Templin et al. (1996b) exposed BDF1 mice to chloroform vapour at concentrations of 0, 149, or 446 mg/m³ (0, 30, or 90 ppm) 6 hours per day for 4 days or 2 weeks (5 days per week). In the kidneys of male mice exposed to 149 or 446 mg/m³, degenerative lesions and 7- to 10-fold increases in cell proliferation were observed. Liver damage and an increased hepatic labelling index were noted in male mice exposed to 149 and 446 mg/m³ and in female mice exposed to 446 mg/m³. Both doses were lethal in groups exposed for 2 weeks (40% and 80% mortality at 149 and 446 mg/m³, respectively).

A 90-day chloroform inhalation study was conducted using male and female B6C3F1 mice and exposure concentrations of 0, 1.5, 10, 50, 149, and 446 mg/m³ (0, 0.3, 2, 10, 30, and 90 ppm) for 6 hours per day, 7 days per week. Large, sustained increases in hepatocyte proliferation were seen in the 446 mg/m³ groups at all time points (4 days and 3, 6, and 13 weeks). In the more sensitive female mice, a NOAEL of 50 mg/m³ for this effect was established. Renal histopathology and regenerative hyperplasia were noted in male mice at 50,
149, and 446 mg/m³ (Larson et al., 1996). In another 90-day inhalation study, F344 rats were exposed to chloroform as concentrations of 0, 10, 50, 149, 446, or 1490 mg/m³ (0, 2, 10, 30, 90, or 300 ppm) for 6 hours per day, 7 days per week. The 1490 mg/m³ level was extremely toxic and deemed by the authors to be inappropriate for chronic studies. Increases in renal epithelial cell proliferation in cortical proximal tubules were observed at concentrations of 149 mg/m³ and above. Hepatic lesions and increased proliferation were noted only at the highest exposure level. In the ethmoid turbinates of the nose, enhanced bone growth and hypercellularity in the lamina propria were observed at concentrations of 50 mg/m³ and above, and a generalized atrophy of the turbinates was seen at all exposure levels after 90 days (Templin et al., 1996c).

Jamison et al. (1996) reported that F344 rats exposed to a high concentration of chloroform vapour (1490 mg/m³ [300 ppm]) for 90 days developed atypical glandular structures lined by intestinal-like epithelium and surrounded by dense connective tissue in their livers. These lesions appeared to arise from a population of cells remote from the bile ducts. The authors also observed a treatment-related increase in transforming growth factor-alpha (TGF-α) immunoreactivity in hepatocytes, bile duct epithelium bile canaliculi, and oval cells and an increase in transforming growth factor-beta (TGF-β) immunoreactivity in hepatocytes, bile duct epithelium, and intestinal crypt-like ducts. The lesions occurred only in conjunction with significant hepatocyte necrosis, regenerative cell proliferation, and increased growth factor expression or uptake.

Palmer et al. (1979) exposed 10 male and 10 female SPF Sprague-Dawley rats to chloroform by intragastric gavage (in toothpaste) daily for 13 weeks. Dose levels were 0, 15, 30, 150, or 410 mg/kg bw per day. At 150 mg/kg bw per day, there was “distinct influence on relative liver and kidney weight” (significance not specified). At the highest dose, there was increased liver weight with fatty change and necrosis, gonadal atrophy in both sexes, and increased cellular proliferation in bone marrow.

### 10.2.3 Bromodichloromethane

Thornton-Manning et al. (1994) administered five consecutive daily BDCM doses to female F344 rats and female C57BL/6J mice by aqueous gavage and found that BDCM is both hepatotoxic and nephrotoxic to female rats (150–300 mg/kg bw per day) but only hepatotoxic to female mice (75–150 mg/kg bw per day). Munson et al. (1982) administered BDCM (50, 125, or 250 mg/kg bw per day) to male and female CD-1 mice by aqueous gavage for 14 days and reported evidence for hepatic and renal toxicity as well as effects on the humoral immune system (decreases in both antibody-forming cells and haemagglutination titres). A subsequent study by French et al. (1999) found no effects of BDCM on immune function. Based on the degree of aspartate aminotransferase and alanine aminotransferase elevations in this study, BDCM was found to be a more potent hepatotoxicant than chloroform, DBCM, and bromoform.

F344/N rats and B6C3F₁ mice were given BDCM by gavage in corn oil 5 days per week for 13 weeks. Rats (10 per sex per dose) were given 0, 19, 38, 75, 150, or 300 mg/kg bw per day. Male mice (10 per dose) were given 0, 6.25, 12.5, 50, or 100 mg/kg bw per day, and female mice were given 0, 25, 50, 100, 200, or 400 mg/kg bw per day. Of the male and female rats that received the highest dose, 50% and 20%, respectively, died before the end of the study. None of the mice died. Body weights decreased significantly in male and female rats given BDCM at 150 or 300 mg/kg bw per day. Centrilobular degeneration of the liver was observed at 300 mg/kg bw.
per day in male and female rats and at 200 and 400 mg/kg bw per day in female mice. Degeneration and necrosis of the kidney were observed at 300 mg/kg bw per day in male rats and at 100 mg/kg bw per day in male mice. The NOAELs in rats were 75 and 150 mg/kg bw per day for body weight reduction and for hepatic and renal lesions, respectively. The NOAEL for renal lesions in mice was 50 mg/kg bw per day (NTP, 1987).

10.2.4 Dibromochloromethane

DBCM-induced cardiotoxicity was reported in male Wistar rats after short-term exposure (4 weeks of daily dosing with 0.4 mmol/kg bw). Arrhythmogenic and negative chronotropic and dromotropic effects were observed, as well as extension of atrioventricular conduction times. Inhibitory actions of DBCM on calcium ion dynamics in isolated cardiac myocytes were also noted (IPCS, 2000).

F344/N rats and B6C3F1 mice (10 per sex per dose) were given DBCM by gavage in corn oil at dose levels of 0, 15, 30, 60, 125, or 250 mg/kg bw per day, 5 days per week for 13 weeks. The final body weights of rats that received 250 mg/kg bw were depressed. A dose-dependent increase in hepatic vacuolation was observed in male rats. Based on this hepatic effect, the NOAEL in rats was 30 mg/kg bw per day. Kidney and liver toxicity were observed in male and female rats and male mice at 250 mg/kg bw per day. Survival rates for treated animals and corresponding controls were comparable except in high-dose rats. Clinical signs in the treated animals and controls were comparable. Based on the renal and hepatic lesions, a NOAEL of 125 mg/kg bw per day was identified in mice (NTP, 1985).

A 90-day corn oil gavage study was conducted using Sprague-Dawley rats and doses of 0, 50, 100, or 200 mg/kg bw per day. Body weight gain was significantly depressed in the high-dose groups to less than 50% and 70% of the controls in males and females, respectively. Observations of liver damage included elevated alanine aminotransferase in mid- and high-dose males, centrilobular lipidosis (vacuolization) in males at all doses and in high-dose females, and centrilobular hepatic necrosis in high-dose males and females. Kidney proximal tubule cell degeneration was induced by DBCM in all high-dose rats and to a lesser extent at 100 mg/kg bw per day in males and at both 50 and 100 mg/kg bw per day in females (Daniel et al., 1990).

10.2.5 Bromoform

Young adult rats (10 per sex per dose) were given bromoform by gavage in corn oil at doses of 0, 12, 25, 50, 100, or 200 mg/kg bw per day, 5 days per week for 13 weeks. Male and female mice were given doses of 0, 25, 50, 100, 200, or 400 mg/kg bw per day. Growth was not affected except at the highest dose in male mice, in which it was slightly suppressed. Male mice at the two highest dose levels showed “minimal to moderate” hepatocellular vacuolation in a few cells. Male rats showed a dose-related increase in hepatocellular vacuolation, which became statistically significant at 50 mg/kg bw per day. The NOAELs for hepatocellular vacuolation were 25 and 100 mg/kg bw per day in male rats and male mice, respectively (NTP, 1989).
10.3 Genotoxicity

10.3.1 Trihalomethanes

All four THMs have induced sister chromatid exchanges (SCE) in human lymphocytes in vitro (bromoform > DBCM > BDCM > chloroform) and in mouse bone marrow cells in vivo (Morimoto and Koizumi, 1983).

In contrast to the predominantly non-genotoxic and non-mutagenic finding for chloroform, the weight of evidence favours a finding of mutagenicity and genotoxicity for the brominated THMs. Pegram et al. (1997) provided evidence that the mutagenic metabolic pathway for brominated THMs is mediated by GSTT1-1 conjugation and that mutagenic effects were not nearly as common with chloroform as with brominated THMs. The ability of GSTT1-1 to mediate the mutagenicity of various brominated THMs and induce almost exclusively GC→AT transitions suggests that it is likely that these THMs are activated by similar pathways (DeMarini et al., 1997).

10.3.2 Chloroform

The current weight of evidence suggests that chloroform is only slightly mutagenic and unlikely to be genotoxic. Varma et al. (1988) reported that chloroform was mutagenic in Salmonella typhimurium without metabolic activation, although a mixture of chloroform (85%) and bromoform (15%) was not mutagenic in the same assay with or without metabolic activation. LeCurieux et al. (1995) and Roldan-Arjona and Pueyo (1993) found that chloroform was not mutagenic with or without metabolic activation using several strains in an S. typhimurium assay. Shelby and Witt (1995) reported that chloroform was genotoxic in a mouse micronucleus assay in B6C3F1 mice but negative in an in vivo chromosomal aberration assay. Pegram et al. (1997) reported chloroform to be mutagenic in S. typhimurium TA1535, although not to the same extent as brominated THMs. Chloroform was not genotoxic in a number of unscheduled DNA synthesis (UDS) and/or repair, micronuclei, chromosomal aberration, and SCE assays (GlobalTox, 2002).

10.3.3 Bromodichloromethane

Although BDCM has given mixed results in bacterial assays for genotoxicity, the results have tended to be positive in tests employing closed systems to overcome the problem of the compound’s volatility (IARC, 1991, 1999; Pegram et al., 1997). LeCurieux et al. (1995) found that BDCM was negative both with and without metabolic activation in the Ames assay. BDCM tested positive in several independent chromosomal aberration assays with and without metabolic activation but was negative in UDS and a mouse micronucleus assay. Fujie et al. (1993) reported that BDCM induced SCE. In addition, Pegram et al. (1997) provided evidence that a mutagenic metabolic pathway for brominated THMs is mediated by GSTT1-1 conjugation.

10.3.4 Dibromochloromethane

DBCM is mostly positive in genotoxicity tests employing closed systems to overcome the problem of volatility (IARC, 1991, 1999; Pegram et al., 1997). DBCM has given mostly positive results in eukaryotic test systems (Loveday et al., 1990; IARC, 1991, 1999; McGregor et al., 1991; Fujie et al., 1993), although there is less consistency in results between the different assays when considered with or without an exogenous metabolic system (WHO, 2005). DBCM
was positive in the Ames test with *S. typhimurium* strain TA100 without activation (Simmon et al., 1977; Ishidate et al., 1982) but negative in strains TA98, TA1535, and TA1537 with or without activation (Borzelleca and Carchman, 1982). It gave positive results for chromosomal aberration in Chinese hamster ovary cells with activation (Ishidate et al., 1982) and for SCE in human lymphocytes and mouse bone marrow cells in *vivo* (Morimoto and Koizumi, 1983); it was negative in the micronucleus assay (Ishidate et al., 1982) and UDS in the liver of rats (IPCS, 2000).

### 10.3.5 Bromoform

There is some evidence to suggest that bromoform may be weakly mutagenic (GlobalTox, 2002). Bromoform, in common with the other brominated THMs, is largely positive in bacterial assays of mutagenicity conducted in closed systems (Zeiger, 1990; IARC, 1991, 1999). Bromoform was positive in the Ames test in *S. typhimurium* strain TA100 without activation (Simmon et al., 1977; Ishidate et al., 1982), positive with and without activation in TA98, and negative or equivocal in strains TA1535 or TA1937 with and without activation (NTP, 1989).

Bromoform gave increased SCE and chromosomal aberrations in mouse and rat bone marrow cells (Morimoto and Koizumi, 1983; Fujie et al., 1990). It gave negative results in mouse bone marrow (Hayashi et al., 1988; Stocker et al., 1997), in the rat liver UDS assay (Pereira et al., 1982; Stocker et al., 1997), and in the dominant lethal assay (Ishidate et al., 1982). In studies carried out by the National Toxicology Program (NTP, 1989), it was positive for micronuclei and SCE, but negative for chromosomal aberrations in mouse bone marrow. Potter et al. (1996) found that bromoform did not induce DNA strand breaks in the kidneys of male F344 rats following seven daily doses of 1.5 mmol/kg bw. As with bacterial assays, bromoform appeared more potent than the other brominated THMs (Morimoto and Koizumi, 1983; Banerji and Fernandes, 1996).

### 10.4 Chronic toxicity/carcinogenicity

#### 10.4.1 Chloroform

Chloroform has been carcinogenic in two animal species in extensive bioassays. In an early study conducted by the National Cancer Institute (NCI), chloroform was administered by gavage in corn oil to groups of 50 male and 50 female Osborne-Mendel rats and B6C3F1 mice. Male rats received 0, 90, or 180 mg/kg bw 5 times per week for 78 weeks; female rats received 0, 125, or 250 mg/kg bw 5 times per week for the first 22 weeks and the same doses as the males thereafter. In the first 18 weeks, doses of 0, 100, or 200 mg/kg bw were administered to male mice, and 0, 200, or 400 mg/kg bw were administered to female mice. After 18 weeks, the doses were changed to 0, 150, and 300 mg/kg bw for male mice and 0, 250, and 500 mg/kg bw for female mice for the remainder of the exposure period (NCI, 1976a).

In male rats, there was a statistically significant dose-related increase in the incidence of carcinomas of the kidney (0/99, 4/50, and 12/50 for control, low doses, and high doses, respectively). These tumours were not observed in female rats, although there was a non-significant increase in tumours of the thyroid (adenocarcinomas and carcinomas) in this sex.

Highly significant increases in hepatocellular carcinomas were observed in both sexes of mice (males: 1/18, 18/50, 44/45; females: 0/20, 36/45, 39/41 for control, low doses, and...
high doses, respectively). Nodular hyperplasia was also observed in low-dose males. It should be noted, however, that the weight loss in exposed animals was greater than 10%.

Upon re-examination of tissue samples from the NCI carcinogenesis bioassay, Reuber (1979) also reported increases in the incidence of several types of benign and malignant tumours of the liver in female rats and malignant lymphomas in both sexes of mice.

In a more recent and larger study, 0, 200, 400, 900, or 1800 mg chloroform/L was administered in drinking water (a more appropriate vehicle than that used in the NCI bioassay described above) to male Osborne-Mendel rats (50–330 animals per group) and female B6C3F1 mice (50–430 animals per group) for 104 weeks; the time-weighted average doses on a body weight basis ranged from 19 to 160 mg/kg bw per day for the rats and from 34 to 263 mg/kg bw per day for the mice (Jorgenson et al., 1985). To increase the sensitivity for detecting low response rates, group sizes were larger for the lower doses; there were two control groups ($n = 330$ and $n = 50$), one of which ($n = 50$) was matched for water intake with the high-dose groups.

In rats, there were dose-related decreases in water consumption and body weight gain that persisted in the two highest dose groups; survival increased with dose, probably as a result of leaner body composition in the higher dose groups (e.g., after 104 weeks, only 12% of controls had survived, whereas 66% of the animals in the high-dose group were still alive; this is a common occurrence in such studies). Consistent with the results of the NCI bioassay described above, there was also a dose-related increase in the incidence of kidney tumours. The incidence of tubular cell adenomas and adenocarcinomas combined was slightly lower than that in the NCI bioassay: 1/50, 4/313, 4/148, 3/48, and 7/50 in the matched control and increasing dose groups, respectively. Although there were increases in other neoplastic lesions in rats, including neurofibromas, leukaemias, lymphomas, and circulatory system tumours, they were not considered to be treatment-related because of a lack of a clear dose–response relationship or statistical significance or because they appeared to be attributable to the longer survival of the chloroform-treated animals.

With respect to the non-neoplastic histopathological changes in the kidney in this study, the authors commented only that “nontumour pathology of the kidney was high in all animals regardless of treatment.” As a result, “it was not possible to relate tumour pathology with other tissue damage on either an individual animal or across-group basis.” The incidence of nephropathy was 91% in the control group, 90% in the matched control, and 95%, 95%, 100%, and 92% in the increasing dose groups, respectively. Kidney tissue from this investigation (Jorgenson et al., 1985) has recently been microscopically re-evaluated for evidence of cytotoxicity and regeneration. Toxic injury in proximal tubular epithelial cells was observed in all high-dose males (1800 mg/L, the dose at which there was a statistically significant increase in tumour incidence) at all time points and approximately half of animals receiving the second highest dose (900 mg/L) for 18 or 24 months. None of the other treatment groups or controls had these characteristic changes. Although a systematic evaluation was not possible due to degradation of the slides and frequent autolytic change, the authors confirmed that such changes were also present in males of the same strain in the 1976 NCI bioassay in which exposure was by corn oil gavage (Hard and Wolf, 1999).

In mice, drinking water consumption was markedly depressed, leading to the death of about 25% of the two highest dose groups and 6% of the next highest dose group in the first week; after this initial period, survival did not differ significantly among groups. In contrast to
the NCI bioassay described above, in which hepatic tumours in both sexes of mice were observed, there were no treatment-related increases in the incidence of any tumours in female mice in this study. Jorgenson et al. (1985) suggested that the hepatic tumours in mice in the NCI study may have been attributable to the interaction of chloroform with the corn oil vehicle.

In different studies in which four strains of mice (C57Bl, CBA, CF/1, and ICI) were administered chloroform for 80 weeks by gavage in toothpaste (0, 17, or 60 mg/kg bw per day in ICI male and female mice) or in toothpaste or arachis oil (0 or 60 mg/kg bw per day in males of all four strains), there were no treatment-related effects on the incidence of any type of tumour in males of three of the four strains (C57Bl, CBA, and CF/1 mice). There was, however, an increase in the incidence of epithelial tumours of the kidney at 60 mg/kg bw per day in male ICI mice, which was greater when chloroform was administered in arachis oil than in toothpaste (Roe et al., 1979).

Several other studies on the potential carcinogenicity of chloroform have been conducted. In B6C3F1 male mice (35 animals per group) ingesting chloroform in drinking water (0, 600, or 1800 mg/L) for periods up to 52 weeks, there were no increases in tumour incidence (Klaunig et al., 1986). However, these results may have been a function of the short observation period or small group sizes. The potential of chloroform to promote tumours induced by known initiators was also investigated in this study. Mice of the same strain (35 animals per group) ingested drinking water containing diethylnitrosamine (DENA) at 10 mg/L for 4 weeks followed by 600 or 1800 mg chloroform/L for up to 52 weeks. There were two control groups: after DENA treatment, the positive control group ingested drinking water containing phenobarbital (500 mg/L), while the vehicle control group received untreated drinking water. The induction of liver tumours was enhanced by exposure to phenobarbital but not by exposure to chloroform after DENA treatment. In contrast, in a study conducted by Deml and Oesterle (1985), chloroform administered in corn oil (100, 200, and 400 mg/kg bw, twice weekly for 11 weeks, 1 week after administration of a single dose of 8 mg DENA) promoted the development of DENA-initiated preneoplastic foci liver tumours in Sprague-Dawley rats.

In a study designed to assess the safety of chloroform in toothpaste, beagle dogs (eight per sex per dose) were given chloroform in a toothpaste base in gelatin capsules, 6 days per week for 7.5 years, at doses of 0, 15, or 30 mg/kg bw per day (Heywood et al., 1979). After 6 weeks of treatment, there were significant increases in serum glutamate–pyruvate transaminase levels in dogs given the high dose. At the low dose level, significant increases were observed at 34 weeks and after. Similar effects were not observed in the vehicle control (16 dogs of each sex) or untreated control (eight dogs of each sex) groups. “Fatty cysts” characterized by aggregations of vacuolated hepatocytes and minimal hepatic fibrosis were observed in animals within each group (including controls). These findings were more frequent and of greater magnitude in animals of either gender treated with chloroform at either dose level than in controls. The LOAEL in this study was 15 mg/kg bw per day.

10.4.2 Mechanism of carcinogenicity for chloroform

Since the previous Canadian drinking water guideline was drafted for total THMs (based on chloroform), significant effort has been made to characterize the mechanism of carcinogenicity and to understand the variability in effects from different routes and vehicles of administration. The current weight of evidence suggests that chloroform is a threshold
carcinogen in rodents. There is strong evidence that the carcinogenic activity of chloroform in both rats and mice is mediated by a non-genotoxic mechanism of action that is secondary to cytotoxicity and cellular proliferation. There is strong evidence that the tumorigenicity of chloroform depends on the rate of its delivery to the target organ, and this suggests that detoxification mechanisms must be saturated before the full carcinogenic potential of chloroform is realized (GlobalTox, 2002). The weight of available evidence also indicates that chloroform has little, if any, capability of inducing gene mutation or other types of direct damage to DNA (IPCS, 2000).

IPCS (2000) summarized the pattern of chloroform-induced carcinogenicity in rodent bioassays conducted up to that time as follows: Chloroform induced hepatic tumours in B6C3F$_1$ mice (males and females) when administered by gavage in corn oil at doses in the range of 138–477 mg/kg bw per day (NCI, 1976a,b). However, when similar doses were administered to the same strain in drinking water, hepatic tumours were not increased (Jorgenson et al., 1985). Liver tumours are observed, therefore, only in mice following administration by gavage in corn oil. This observation is consistent with those in initiation/promotion assays in which chloroform has promoted development of liver tumours, particularly when administered by gavage in a corn oil vehicle.

Chloroform also induces renal tumours, but at lower rates than liver tumours in mice. Chloroform induced kidney tumours in male Osborne-Mendel rats at doses of 90–200 mg/kg bw per day in corn oil by gavage (NCI, 1976a,b). However, in this strain, results were similar when the chemical was administered in drinking water, indicating that the response is not entirely dependent on the vehicle used (Jorgenson et al., 1985). It should be noted, however, that at the higher doses in this study, there were significant reductions in body weight. In an early, more limited investigation, kidney tumours were increased in ICI mice but not in CBA, C57BL, or CF1 mice administered chloroform by gavage in toothpaste (Roe et al., 1979). Therefore, the tumorigenic response in the kidney, although observed in both rats and mice (males), is highly strain-specific.

To investigate the possible role of replicative proliferative effects in the carcinogenicity of chloroform, a wide range of studies have been conducted in which replicative proliferative effects have been examined in similar strains of rats and mice exposed to similar doses or concentrations of chloroform, although for shorter periods, as in the principal carcinogenesis bioassays (Larson et al., 1993, 1994a,b,c, 1995a,b, 1996; Lipsky et al., 1993; Pereira, 1994; Templin et al., 1996a,b,c). Most of these studies involved evaluation of histopathological changes and cell proliferation in the kidney and liver, the latter determined as a BrdU labelling index in histological tissue sections. Results of available studies also indicate that the proliferative response is less when exposure is not continuous (e.g., inhalation for 5 days per week versus 7 days per week) (Larson et al., 1996; Templin et al., 1996c) and returns to baseline following a recovery period.

Based on studies conducted primarily in the F344 rat, available data are consistent with a mode of action for carcinogenicity in the kidney based on tubular cell regeneration. Studies in this strain indicate that chloroform causes damage and increases cell replication in the kidney at doses similar to those that induce tumours in Osborne-Mendel rats following gavage in corn oil for periods up to 3 weeks (Larson et al., 1995a,b). However, there has been no clear dose–response for renal damage or proliferation in F344 rats exposed to concentrations in...
drinking water that were similar to those that induced tumours in Osborne-Mendel rats in the
carcinogenesis bioassay of Jorgensen et al. (1985) (Larson et al., 1995b). In a single study in
which the proliferative response was compared in F344 and Osborne-Mendel rats at 2 days
following a single gavage administration, it was concluded that these strains were about equally
susceptible to chloroform-induced renal injury, although a statistically significant increase in
labelling index was observed at a much lower dose in the Osborne-Mendel rat (10 mg/kg bw)
than in the F344 rat (90 mg/kg bw); this latter observation may have been a function of the low
value in controls for the Osborne-Mendel rats.

Data on the proliferative response in the strain in which renal tumours have been
observed (Osborne-Mendel rats) are limited to examination at 2 days following a single
administration by gavage in corn oil (Templin et al., 1996b); studies in which the proliferative
response was examined in Osborne-Mendel rats following administration in drinking water have
not been identified. Although the results of this study are not inconsistent with a mode of action
of induction of tumours based on tubular cell regeneration, they are considered inadequate in
themselves to quantitatively characterize the dose–response relationship for an intermediate
endpoint for cancer induction (IPCS, 2000).

Environment Canada and Health Canada (2001) also discussed the weight of evidence for
the mechanism of carcinogenicity for chloroform. This report stated that for Osborne-Mendel
rats, the results of re-analyses of the original renal tissues (Hard and Wolf, 1999; Hard et al.,
2000), from both the drinking water bioassay (Jorgenson et al., 1985) and the gavage study
(NCI, 1976a), have been critical. They provide strong support for the argument that the mode
of induction of these tumours is consistent with the hypothesis that sustained proximal tubular cell
damage is a requisite precursor lesion for chloroform-induced tumours.

When comparing short-term studies in rats and mice using similar chloroform exposure
regimens, the experimental conditions employed in studies that led to cellular proliferation and
cytotoxicity led to tumour formation when employed in cancer bioassays. However, the converse
is not always true.

The hypothesized mode of carcinogenesis for chloroform is in keeping with the growing
body of evidence supporting the biological plausibility that prolonged regenerative cell
proliferation can be a causal mechanism in chemical carcinogenesis. This has been addressed in
numerous articles, including Ames and Gold (1990, 1996), Cohen and Ellwein (1990, 1991,
Cunningham and Matthews (1995), Butterworth (1996), Farber (1996), and Stemmermann et al.
(1996).

In summary, chloroform has induced liver tumours in mice and renal tumours in mice
and rats. The weight of evidence of genotoxicity, sex and strain specificity, and concordance
of cytotoxicity, regenerative proliferation, and tumours is consistent with the hypothesis that
cytotoxicity with a period of sustained cell proliferation likely represent a secondary mechanism
for the induction of tumours following exposure to chloroform. This is consistent with a non-
linear dose–response relationship for induction of tumours. This cytotoxicity is primarily related
to rates of oxidation of chloroform to reactive intermediates, principally phosgene and
hydrochloric acid. The weight of evidence for this mode of action is strongest for hepatic and
renal tumours in mice and more limited for renal tumours in rats (Environment Canada and
There has been little evidence to support other mechanisms of carcinogenicity, especially at low doses where cytotoxicity and cellular proliferation are not expected. Chloroform toxicity is clearly enhanced in rodents when administered in corn oil, compared with when it is received in drinking water, supporting the hypothesis that tumorigenicity of chloroform depends on the rate of its delivery to the target tissue and further suggesting that detoxification mechanisms must be saturated before the full carcinogenic potential of chloroform is realized (GlobalTox, 2002).

10.4.3 Bromodichloromethane

In one carcinogenesis bioassay conducted for BDCM, groups of 50 male and 50 female F344/N rats and B6C3F₁ mice were administered the compound by gavage in corn oil, 5 days per week for 102 weeks. Rats received 0, 50, or 100 mg/kg bw per day; male mice received 0, 25, or 50 mg/kg bw per day, while female mice received 0, 75, or 150 mg/kg bw per day (NTP, 1987).

In rats, there was some decrease in body weight gain in the high-dose groups of both sexes (statistical significance not specified), increased incidence of cytomegaly of the renal tubular epithelial cells in males (both doses), nephrosis in the high-dose group of females, and hepatic changes, including necrosis, clear cell change, eosinophilic cytoplasmatic change, focal cellular change, and fatty metamorphosis, in both sexes, but predominantly in the high-dose group of females. There was clear evidence of carcinogenicity in male and female rats, with increases in the incidence of renal tubular cell adenomas and adenocarcinomas (combined incidence in control, low-dose, and high-dose groups: males, 0/50, 1/50, and 13/50; females, 0/50, 1/50, and 15/50) and rare tumours (adenomatous polyps and adenocarcinomas) of the large intestine (combined incidence: males, 0/50, 13/50, and 45/50; females, 0/46, 0/50, and 12/47). Increased incidence of skin neoplasms in low- but not high-dose male rats was also observed but was not considered to be compound-related. The neoplasms of the kidney in rats in this bioassay were not similar to those observed for other compounds, such as 1,4-dichlorobenzene, for which tumours occurred principally in males and were associated with severe nephropathy and increased incidence of calcification and hyaline droplet formation, associated with reabsorption of alpha-2-microglobulin (Charbonneau et al., 1989).

There was a decrease in body weight gain of female mice, and survival was significantly lower than that of controls, due partly to ovarian abscesses not considered to be treatment-related. The incidence of renal cytomegaly and hepatic fatty metamorphosis in male mice was also increased. Pathological changes in the thyroid gland and testis were also observed but were not considered to be treatment-related. There was also clear evidence of carcinogenicity in male and female B6C3F₁ mice, based on increased incidence of adenomas and adenocarcinomas (combined) of the kidney in males (incidence in control, low-dose, and high-dose groups, 1/49, 2/50, and 9/50, respectively) and of hepatocellular adenomas and carcinomas (combined) in female mice (incidence 3/50, 18/48, and 29/50, respectively).

Moore et al. (1994) administered BDCM in drinking water (containing 0.25% Emulphor) to male F344 rats and B6C3F₁ mice for 1 year and evaluated clinical indicators of kidney toxicity. Water containing BDCM concentrations of 0.08, 0.4, and 0.8 g/L for rats and 0.06, 0.3, and 0.6 g/L for mice resulted in average daily doses of 4.4, 21, and 39 mg/kg bw for rats and 5.6, 24, and 49 mg/kg bw for mice. A urinary marker for renal proximal tubule damage, N-acetyl-β-glucosaminidase, was elevated above controls in each dose group in rats and at the highest
treatment level in mice. Significant increases in urinary protein, indicative of glomerular damage, were also noted in low- and mid-dose rats as well as high-dose mice.

While cytotoxic effects of BDCM may potentiate tumorigenicity in certain rodent tissues at high dose levels, direct induction of mutations by BDCM metabolites may also play a carcinogenic role. The extent to which each of these processes contributes to the induction of tumours observed in chronic animal studies is, however, questionable (IPCS, 2000).

DeAngelo et al. (2002) examined the ability of THMs administered in drinking water to induce aberrant crypt foci in the colons of B6C3F1 mice and F344/N rats. Preneoplastic aberrant crypt foci were induced in the colon of rats following the administration of some brominated THMs. However, unlike DBCM and bromoform, colon neoplasms were not found upon chronic administration of BDCM to rats via drinking water. BDCM did, however, induce colon cancer in male rats when administered in corn oil gavage.

In a recent draft study from NTP (2004), male F344/N rats and female B6C3F1 mice were exposed to BDCM in drinking water for 2 years. Groups of 50 male F344/N rats were exposed to target concentrations equivalent to average daily doses of 0, 6, 12 or 25 mg/kg bw BDCM. Survival and mean body weights of all exposed groups were generally similar to those of the controls throughout the study. There were no increased incidences of neoplasms that were attributed to BDCM. The incidences of chronic inflammation in the liver of the two higher dose groups were significantly greater than that in the controls; however, the biological significance of these increases is uncertain. Groups of 50 female B6C3F1 mice were exposed to target concentrations equivalent to average daily doses of 0, 9, 18 or 36 mg/kg bw BDCM. Survival of exposed groups was similar to that of the controls, but mean body weights of all exposed groups were generally less than those of the controls from week 4 through the end of the study. The incidences of hepatocellular adenoma or carcinoma occurred with a negative trend, and the incidence in the higher dose group was significantly decreased relative to the control group. The incidence of haemangiosarcoma in all organs was significantly decreased in the 18 mg/kg bw group.

The authors of the study concluded that under the conditions of this 2-year drinking water study, there was no evidence of carcinogenic activity of BDCM in male F344/N rats exposed to target concentrations of 6, 12 or 25 mg/kg bw and in female B6C3F1 mice exposed to target concentrations of 9, 18 or 36 mg/kg bw (NTP, 2004). However, this report has not yet been peer-reviewed and as such is not final, and cannot be used in the risk assessment at this time.

10.4.4 Dibromochloromethane

In a National Toxicology Program (NTP) carcinogenesis bioassay, DBCM was administered in doses of 0, 40, or 80 mg/kg bw by gavage in corn oil 5 times per week for 104 weeks to groups of 50 male and female F344/N rats. In addition, 0, 50, or 100 mg/kg bw per day was administered in similar fashion to groups of 50 male and female B6C3F1, mice 5 days per week for 105 weeks. Body weight gain in the high-dose group of male rats was decreased, and there was a dose-related increase in lesions (fatty metamorphosis and ground-glass cytoplasmic changes) of the liver in both sexes and nephrosis of the kidney (dose-related) in females. There was, however, no evidence of carcinogenicity in rats (NTP, 1985).

In male mice, survival was significantly lower in both dose groups, and 35 animals in the low-dose group were accidentally killed during weeks 58–59. In both sexes, the incidences of
hepatic lesions were increased, including fatty metamorphosis (both sexes), hepatocellular necrosis (dosed males), hepatocytomegaly (high-dose males), and calcification of the liver (high-dose females). Nephrosis (high dose) and renal calcification in males and follicular cell hyperplasia of the thyroid gland (possibly related to a bacterial infection) in females were also increased. There was equivocal evidence of carcinogenicity in male B6C3F1 mice based on an increased incidence of hepatocellular carcinomas, but only a marginal increase in hepatocellular adenomas or carcinomas (combined) (incidence of hepatocellular carcinomas in control and high-dose groups, 10/50 and 19/50, respectively; incidence of hepatocellular adenomas and carcinomas combined, 23/50 and 27/50, respectively). The number of surviving animals in the low-dose group of male mice, however, was inadequate for analysis of tumour incidence, owing to a dosing error. There was also some evidence of carcinogenicity in female mice, based on an increased incidence of hepatocellular adenomas and hepatocellular adenomas or carcinomas (combined). The incidence of hepatic adenomas and carcinomas (combined) in the control, low-dose, and high-dose groups was 6/50, 10/49, and 19/50, respectively.

Mechanistic issues for DBCM are similar to those addressed for BDCM.

10.4.5 Bromoform

In an NTP carcinogenesis bioassay, 0, 100, or 200 mg bromoform/kg bw was administered by gavage in corn oil 5 days per week for 103 weeks to groups of 50 F344/N rats of each sex and to female B6C3F1 mice (NTP, 1989). Male B6C3F1 mice were administered 0, 50, or 100 mg/kg bw on the same schedule. In rats, there was a reduction of body weight gain in low- and high-dose males and high-dose females; survival in the high-dose group of males was also significantly lower than that in controls. As well, dose-related, non-neoplastic effects in the salivary gland (squamous metaplasia and chronic active inflammation in both sexes), prostate (squamous metaplasia), forestomach (ulcers in the males), lung (chronic active inflammation — males only), and spleen (pigmentation — high-dose females) were also observed, although the lesions of the salivary gland and lung were characteristic of infection by rat corona virus, to which a positive serological reaction was observed early in the study. There was some evidence of carcinogenicity in male rats and clear evidence in female rats, based on increased incidences of uncommon neoplasms (adenomatous polyps and adenocarcinomas of the large intestine) in both sexes. The incidences of these tumours (combined) in the control, low-dose, and high-dose groups of females were 0/50, 1/50, and 8/50, respectively; in males, the comparable values were 0/50, 0/50, and 3/50. Although the incidence of these tumours in females was similar to that observed in the NTP bioassay for BDCM, the incidence in males was much less. Reduced survival in the high-dose group of male rats administered bromoform may, however, have lowered the sensitivity of the bioassay for detecting a carcinogenic response. The incidence of neoplastic nodules in low-dose female rats was also greater than that in controls, but it was not considered to be a chemically induced neoplastic effect, as the lesions did not fit the current NTP criteria for hepatocellular adenomas, nor was the incidence significantly increased in high-dose female rats or in dosed male rats.

In female mice, there was a decrease in body weight gain and survival (partially attributable to utero-ovarian infection) and increases in the incidence of follicular cell hyperplasia of the thyroid (high dose) and fatty change of the liver (both doses). There was no evidence of carcinogenicity in male or female mice (NTP, 1989).
Bromoform was administered in drinking water (containing 0.25% Emulphor) to male F344 rats and B6C3F1 mice for 1 year, and clinical indicators of kidney toxicity were examined (Moore et al., 1994). Water containing bromoform concentrations of 0.12, 0.6, and 1.2 g/L for rats and 0.08, 0.4, and 0.8 g/L for mice resulted in average daily doses of 6.2, 29, or 57 mg/kg bw for rats and 8.3, 39, or 73 mg/kg bw for mice. Several indicators of tubular and glomerular damage were elevated at each treatment level in mice, and mice appeared more susceptible to the nephrotoxic effects of bromoform than to those of BDCM. As in mice, urinary protein was increased in all rat dose groups, but little evidence of loss of tubule function was observed in rats.

Although bromoform seems to have a greater propensity for metabolism and is a more potent mutagen than BDCM, it appears to be a less potent toxicant and carcinogen based on the results of the NTP (1985, 1987) bioassays and numerous other in vivo studies of toxicity. As with DBCM, a possible explanation is less bioavailability resulting from the greater lipophilicity of this compound and the use of corn oil as the vehicle of administration. This concept may be supported by the occurrence of bromoform-induced tumours in the intestinal tract, but not in the liver or kidneys. Greater lipophilicity and reactivity of bromoform metabolites may also prevent it from reaching critical target sites. Moreover, when bromoform was injected intraperitoneally, its metabolism was greater than that of the other THMs (Anders et al., 1978; Tomasi et al., 1985). When administered by corn oil gavage, however, bromoform was the least metabolized THM (Mink et al., 1986).

10.5 Reproductive and developmental toxicity

10.5.1 Trihalomethanes

The teratogenicity of THMs was investigated in one study in which BDCM, DBCM, or bromoform at doses of 50, 100, or 200 mg/kg bw per day or chloroform at doses of 100, 200, or 400 mg/kg bw per day was administered to groups of 15 pregnant Sprague-Dawley rats by oral intubation in corn oil on gestation days 6–15. Maternal weight gain was depressed in the high-dose groups (200 mg/kg bw per day) receiving BDCM and DBCM, but to a lesser extent than that in the high-dose group for chloroform (400 mg/kg bw per day). Maternal liver weight was also increased at the highest dose of BDCM (200 mg/kg bw per day). BDCM and bromoform were considered to be fetotoxic, based on the observation of interparietal anomalies, although the statistical significance of the observed increases was not reported. These compounds also appeared to increase the incidence of aberrations of the sternebrae. The LOAEL based on this fetotoxic effect was 50 mg/kg bw per day (Ruddick et al., 1983).

A survey of available toxicological literature on reproductive and developmental effects of DBPs including chloroform and BDCM was conducted for the U.S. EPA by Tyl (2000), who concluded that current published studies are not sufficient for quantitative assessment of reproductive or developmental risk but are sufficient for determination of hazard. The potential hazards identified for chloroform and BDCM were whole litter resorption and fetotoxicity, and for BDCM, male reproductive toxicity (Tyl, 2000).

10.5.2 Chloroform

Available data on the teratogenicity of the THMs are confined principally to chloroform. In studies conducted to date, chloroform has not been teratogenic in rats, rabbits, or mice at
doses up to 400 mg/kg bw following administration by gavage in corn oil or emulphor:saline (Thompson et al., 1974; Burkharter and Balster, 1979; Ruddick et al., 1983). Fetotoxic effects (e.g., decreased body weights and sternebral and interparietal malformations) were sometimes observed, but only at doses that were toxic to the mothers.

In a continuous breeding study, male and female CD-1 mice were administered chloroform in corn oil by gavage at actual doses of 0, 6.6, 15.9, or 41.2 mg/kg bw per day for 7 days prior to and throughout the 98-day cohabitation period. Control and high dose F₁ pups were administered chloroform after weaning at postnatal day 21 according to the same dosing schedule as their F₀ parents. There were no significant effects on fertility or reproduction in either gender over two generations. Histopathological changes indicative of hepatotoxicity were observed in the F₁ females in all treatment dose levels (Gulati et al., 1988).

Hoechst (1991) examined the embryotoxicity and developmental toxicity of inhaled chloroform. Female Wistar rats were mated, then exposed by whole-body inhalation to chloroform at 0, 15, 50, or 149 mg/m³ (0, 3, 10, or 30 ppm) for 7 hours per day between gestation days 7 and 16. Slight reductions in food consumption and significant reductions in body weights were observed in dams exposed at 50 and 149 mg/m³. These findings were hypothesized to result in the slight stunting of fetuses produced in these animals. A NOAEL of 15 mg/m³ was established based on the lack of embryotoxicity or teratogenicity (GlobalTox, 2002).

10.5.3 Bromodichloromethane

Narotsky et al. (1997) examined the effects of BDCM in F344 rats using doses of 0, 25, 50, or 75 mg/kg bw per day in aqueous or oil gavage vehicles. BDCM induced full-litter resorptions in the 50 and 75 mg/kg bw per day dose groups with either vehicle of administration. For dams receiving corn oil, full-litter resorptions (FLR) were noted in 8% and 83% of the litters at 50 and 75 mg/kg bw per day, respectively. All vehicle control litters and litters from the group given 25 mg/kg bw per day survived the experimental period. BDCM had been shown to cause maternal toxicity at these doses in a previous study (Narotsky et al., 1992).

In a developmental study conducted by Christian et al. (2001), Sprague-Dawley rats and New Zealand White rabbits were dosed with BDCM continuously in drinking water on gestation days 6–21 in rats and gestation days 6–29 in rabbits. Mean consumed doses were 0, 2.2, 18.4, 45.0, or 82.0 mg/kg bw per day for rats and 0, 1.4, 13.4, 35.6, or 55.3 mg/kg bw per day for rabbits. In rats, water consumption was reduced in all treatment doses, and body weight gain and feed consumption were reduced at ≥45.0 mg/kg bw per day. In rabbits, body weight gain and feed consumption were reduced at ≥35.6 mg/kg bw per day. The maternal NOAELs were 18.4 and 13.4 mg/kg bw per day for rats and rabbits, respectively. Minimal delays in the ossification of forepaw phalanges and hindpaw metatarsals and phalanges occurred in rat fetuses at 82.0 mg/kg bw per day and were considered marginal, reversible, and associated with severely reduced maternal weight gain. There were no treatment-related effects observed in rabbit fetuses. The developmental NOAELs were 45.0 and 55.3 mg/kg bw per day for rats and rabbits, respectively (Christian et al., 2001).

In a two-generation reproduction study conducted by Christian et al. (2002), Sprague-Dawley rats were treated with BDCM continuously via the drinking water at concentrations of 0, 50, 150, or 450 mg/L (equal to 0, 4.1–12.6, 11.6–40.2, or 29.5–109.0 mg/kg bw per day). In the
two top dose groups, mortality and clinical signs associated with reduced water consumption, reduced body weights and weight gains, and reduced food consumption were observed. Reduced body weights were associated with reduced organ weights and increased organ weight ratios. Small delays in sexual maturation (preputial separation, vaginal patency) and more F₁ rats with prolonged diestrus were also attributed to severely reduced body weights. The NOAEL for general toxicity and the NOAELs for reproductive and developmental toxicity were at least 4.1–12.6 mg/kg bw per day. If the delayed sexual maturation associated with severely reduced body weights is considered general toxicity, reproductive and developmental NOAELs for BDCM are greater than 29.5–109.0 mg/kg bw per day (Christian et al., 2002).

Bielmeier et al. (2001) investigated rat strain sensitivity between F344 and Sprague-Dawley rats as measured by FLR after dosing with BDCM. Following aqueous gavage with BDCM at 75 mg/kg bw per day on gestation days 6–10, F344 rats had a 62% incidence of FLR, whereas all SD rats maintained their litters. Additionally, rats treated with BDCM at 75 mg/kg bw per day on gestation days 6–10, the critical period encompassing the luteinizing hormone (LH)-dependent period of pregnancy, had a 75% incidence of FLR, but rats treated on gestation days 11–15 with BDCM at 75 or 100 mg/kg bw per day were unaffected. Twenty-four hours after a single dose, all dams with FLR had markedly reduced serum progesterone levels; however, LH levels were unaffected. The high FLR rate during the LH-dependent period, the lack of response thereafter, and the reduced progesterone levels without an associated reduction in LH levels suggest that BDCM disrupts luteal responsiveness to LH (GlobalTox, 2002).

Klinefelter et al. (1995) studied the potential of BDCM to alter male reproductive function in F344 rats. BDCM was consumed in the drinking water for 52 weeks, resulting in average dose rates of 22 and 39 mg/kg bw per day. No gross lesions in the reproductive organs were revealed by histological examination, but exposure to the high BDCM dose significantly decreased the mean straight-line, average path, and curvilinear velocities of sperm recovered from the cauda epididymis (IPCS, 2000).

Chen et al. (2003) examined the effect of BDCM on chronic gonadotrophin secretion by human placental trophoblast cultures. A BDCM dose-dependent reduction in the secretion of bioactive and immunoreactive chorionic gonadotrophin from human placental trophoblasts was observed, suggesting that BDCM targets these cells. A reduction in chorionic gonadotrophin could have adverse effects on pregnancies, since this hormone plays a vital role in maintaining pregnancy.

10.5.4 Dibromochloromethane

In a multigeneration reproduction study, groups of 10 male and 30 female ICR mice were treated with DBCM in Emulphor at 0, 0.1, 1.0, or 4.0 g/L (0, 17, 171, or 685 mg/kg bw per day) in drinking water for 35 days, then mated; subsequent re-matings occurred 2 weeks after weaning. The F₁ mice were treated with the same test solution for 11 weeks after weaning and then mated; re-mating occurred 2 weeks after weaning. At 17 mg/kg bw per day, there was only a slight depression in the body weight of the newborn pups in the F₂ generation. At 171 mg/kg bw per day, there was a significant decrease in female body weight and an increase in the occurrence of gross liver pathology of F₀ and F₁b mice; the lesions varied in severity from fat accumulation to distinct masses on the liver surface. Although not occurring in every generation, there were significant decreases in litter size, pup viability, postnatal body weight, and lactation.
index. At 685 mg/kg bw per day, the effects were of the same types but more severe. Body weight gain was significantly reduced in both males and females at the highest dose (685 mg/kg bw per day) and in females at the middle dose (171 mg/kg bw per day). Animals in both these groups exhibited enlarged livers with gross morphological changes. In addition, the gestation index, fertility, and survival of the F₁ generation were significantly reduced. Only fertility was decreased (high dose) in the F₂ generation (IPCS, 2000). Based on maternal toxicity and fetotoxicity, a NOAEL of 17 mg/kg bw per day was identified (Borzelleca and Carchman, 1982).

10.5.5 Bromoform

Bromoform was found to induce FLR in pregnant F344 rats when administered orally on gestation days 6–15, but at higher doses (150 and 200 mg/kg bw per day) than those required to produce the same effect for BDCM (Narotsky et al., 1993).

The effect of bromoform on fertility and reproduction was investigated in Swiss CD-1 mice (20 pairs per dose) dosed for 105 days at 0, 50, 100, or 200 mg/kg bw per day in corn oil by gavage. No apparent effect on fertility or reproduction (e.g., litters per pair, live pups per litter, sex of live pups, pup body weights) was reported in either the parental or the F₁ generation, and a reproductive NOAEL of 200 mg/kg bw per day was identified (NTP, 1989).

10.6 Neurotoxicity

Neurotoxicological findings reported for the THMs are observations of anaesthesia associated with acute high-dose exposures to brominated THMs (bromoform, BDCM, DBCM) and results from a behavioural study conducted by Balster and Borzelleca (1982) in adult male mice dosed by aqueous gavage for up to 90 days. Treatment with 1.2 or 11.6 mg/kg bw per day was without effect in various behavioural tests, and dosing for 30 days with 100 mg/kg bw per day did not affect passive avoidance learning. Animals dosed with either 100 or 400 mg/kg bw per day for 60 days exhibited decreased response rates in an operant behaviour test. These effects were greatest early in the regimen, with no evidence of progressive deterioration (IPCS, 2000).

11.0 Classification and assessment

There is insufficient data on each of the individual THMs identified in this document to establish distinct guidelines for each. Rather, the approach chosen is to establish a MAC for THMs as a group, based on Chloroform data, and a separate MAC for BDCM.

11.1 Trihalomethanes (chloroform)

As chloroform is the THM present in greatest concentration in drinking water, and the THM for which there are most scientific data available, a guideline developed based on data for this compound should be applicable as a guideline for the THMs identified in this document (chloroform, bromodichloromethane, dibromochloromethane and bromoform). Although not complete, available epidemiological data are consistent with the hypothesis that ingestion of chlorinated drinking water, if not THMs specifically, may be associated with cancers of the bladder and colon (Krasner et al., 1989). Additionally, epidemiological data available since 1993 have associated adverse reproductive outcomes with exposure to THMs, although neither clear evidence of a threshold, nor a dose–response pattern of increasing risk with increasing concentration of total THMs, has been found (Reif et al., 2000).
Chloroform has been classified in Group IIIC in this assessment, possibly carcinogenic to humans based on inadequate evidence for carcinogenicity in humans but limited evidence in experimental animals (Health Canada, 1994). There is compelling mechanistic evidence that both the hepatic and renal tumorigenic responses observed in previous carcinogenicity studies of chloroform (NCI, 1976a; Jorgenson et al., 1985) are mediated by a non-genotoxic mechanism (IPCS, 2000). One of the hypothesized modes of action for chloroform for tumour induction in rodents includes the following requisite precursor steps to cancer: 1) metabolism of chloroform by the target cell population; 2) induction of sustained cytotoxicity by metabolites; and 3) subsequent persistent regenerative cell proliferation (Environment Canada and Health Canada, 2001).

The nature of the vehicle appears to be an important factor in the toxicity and carcinogenicity of chloroform. More marked hepatotoxic effects and increased incidence of liver tumours in rats and mice are observed following administration of chloroform in corn oil compared with drinking water, probably as a result of the major shift in the nature of the caloric intake associated with the former vehicle. PBPK modelling was performed for chloroform in the 2001 CEPA assessment report in order to estimate doses causing toxicity in specific organs. Basing the calculation of a Canadian drinking water guideline on the PBPK approach would lead to a considerable raising of the MAC. Given the uncertainties surrounding the health effects of THMs in drinking water in humans and that chloroform is used as a surrogate for THMs, it is considered appropriate to use the more conservative tolerable daily intake (TDI) approach for calculating the MAC.4

Two key studies were considered in the risk assessment for chloroform: the Heywood et al. (1979) study in dogs and the Larson et al. (1994b) study in mice. The target organ in both studies was the liver. Although the Heywood et al. (1979) study was conducted in a relatively higher mammalian species (dog) and was of a reasonably long duration (7.5 years), it is an older study, used gavage dosing with a toothpaste base in a capsule, and did not cover the full life span of the dog. The Larson et al. (1994b) study, on the other hand, was conducted in a relatively lower mammalian species (mouse), used either corn oil vehicle (which may have influenced the pharmacokinetics and toxicity of the test compound) by gavage or drinking water given ad libitum, and was of short duration (3 weeks), which is insufficient for proper assessment of a lifetime exposure.

The NOAEL for treatment-related changes in the liver (cytolethality and regenerative hyperplasia) established in the mouse study (Larson et al., 1994b) with chloroform in corn oil vehicle was 10 mg/kg bw per day (corrected to 7 mg/kg bw per day due to 5 days per week dosing). In the same study (Larson et al., 1994b), however, mice treated with chloroform administered via drinking water had no treatment-related changes up to a dose of 329 mg/kg bw per day. In the Heywood et al. (1979) dog study, treatment-related liver changes (fatty cysts) were observed at the lowest administered dose (LOAEL = 15 mg/kg bw per day corrected to 13 mg/kg bw per day due to 6 days per week dosing), and no NOAEL was established.

4 Consistent with this approach, the U.S. EPA did not use PBPK modelling to estimate the delivered dose (i.e., the amount of key chloroform metabolites that actually reach the liver and cause cell toxicity) in their 2001 National Primary Drinking Water Regulations. It was felt that the required toxicokinetic data were not available. Thus, the reference dose used to support their maximum concentration limit goal for drinking water was calculated using the applied dose (i.e., the amount of chloroform ingested) (U.S. EPA, 2001).
The Heywood et al. (1979) dog study was chosen as the most appropriate study for risk assessment, due to its long duration and the possible influence of the corn oil vehicle on the effects observed in the short-term Larson et al. (1994b) mouse study. The TDI is calculated as follows:

\[
\text{TDI} = \frac{13 \text{ mg/kg bw per day}}{2100} \approx 0.0062 \text{ mg/kg bw per day}
\]

where:

- 13 mg/kg bw per day is the LOAEL in the Heywood et al. (1979) dog study, corrected from 15 mg/kg bw per day to 13 mg/kg bw per day due to 6 days per week dosing,
- 2100 is the uncertainty factor (×10 for intraspecies variation; ×10 for interspecies variation; ×7 for less-than-lifetime exposure; ×3 for use of a LOAEL instead of a NOAEL). A moderate uncertainty factor of 7 was chosen for the less-than-lifetime exposure because 7.5 years was considered a reasonably long duration in the dog’s life span. A modest uncertainty factor of 3 was used for the use of a LOAEL, because of the subtle nature of the endpoint (fatty cysts) observed in the dog study. Further support for this uncertainty factor is given by the absence of effects seen in the liver at a considerably higher dose of up to 329 mg/kg bw per day when chloroform was applied in drinking water in what appeared to be a more sensitive species (mouse).

The health-based target for THMs (based on chloroform) can be calculated as follows:

\[
6.2 \, \mu\text{g/kg bw per day} \times 70 \, \text{kg} \times 0.80 \approx 80 \, \mu\text{g/L} \text{ (rounded)}
\]

\[
4.11 \, \text{Leq/d}
\]

where:

- 6.2 μg/kg bw per day is the TDI, as derived above,
- 70 kg is the average adult body weight,
- 0.80 is the allocation factor based on CEPA estimates (Environment Canada and Health Canada, 2001), and considering that chloroform is an important DBP in treated water. Of all media of exposure, drinking water is the main source of exposure to chloroform.
- 4.11 Leq/d is the total exposure contribution from drinking water (see section on Multiroute Exposure through Drinking Water).

11.2 Bromodichloromethane

BDCM is used as an indicator of the presence of brominated THMs, but the MAC developed applies to the level of BDCM in drinking water.

Genotoxicity studies indicate that BDCM is weakly mutagenic, probably as a result of glutathione conjugation. Carcinogenicity studies show that, BDCM administered to rats by gavage in corn oil for 102 weeks at doses ranging from 50 to 100 mg/kg bw per day, resulted in increased incidences of renal tubular cell adenomas and adenocarcinomas affecting both sexes and a markedly increased incidence of large intestinal tumours (combined adenomas and carcinomas) in both sexes. In mice, BDCM administered by gavage in corn oil for 102 weeks at
dose levels of 0, 25, or 50 mg/kg bw per day or 0, 75, or 150 mg/kg bw per day in males and females, respectively, caused renal cytomegaly and hepatic fatty metamorphosis, increased incidences of renal tubular adenomas and carcinomas in males, and an increased incidence of combined hepatocellular adenomas and carcinomas in females. These carcinogenicity studies are supported by epidemiological studies showing an apparent association between the THM group of compounds and colorectal cancer in humans.

BDCM has been classified in Group II — probably carcinogenic to humans, with sufficient evidence in animals and inadequate evidence in humans (Health Canada, 1994). Among the four THMs commonly found in drinking water, BDCM appears to be the most potent rodent carcinogen. BDCM caused tumours at lower doses and at more target sites than for any of the other THMs (IPCS, 2000).

The tumours of the large intestines (combined adenomatous polyps and carcinomas) in rats were chosen for the cancer risk assessment, as they occurred with the highest frequency and affected both sexes in the study, and because of the apparent epidemiological association of this group of compounds (THMs) with colorectal cancer in humans. Furthermore, these tumours appear most likely to be associated with a mutagenic mechanism, as they were not associated with underlying cytotoxicity or other non-epigenetic mechanism. The combined large intestinal tumours had high unit risk value, equal to or higher than the unit risks for the other tumour types (kidney and liver) identified in carcinogenicity studies with this compound.

Cancer risks have been estimated on the basis of the results of the only adequate carcinogenesis bioassay in F344/N rats, which was conducted by the NTP in 1987. It should be noted, however, that the compound was administered by gavage in corn oil in this bioassay and that quantitative risks may be overestimated. Although there has been one carcinogenesis bioassay in which BDCM was administered in a more appropriate vehicle (i.e., drinking water) (Tumasonis et al., 1985), it was considered inadequate for quantitative risk estimation, based on the limitations mentioned in the Chronic Toxicity/Carcinogenicity section. Moreover, the increases in adenomas and adenocarcinomas in the kidney of male mice and in hepatocellular adenomas and carcinomas in female mice in the NTP bioassay have not been used for quantitative estimation of the cancer risks, because these increases were confined to one sex and because of the possible contribution of the corn oil vehicle to the induction of liver tumours in mice.

Based on the tumours that were significantly increased in F344/N rats in the NTP (1987) bioassay (i.e., intestinal adenomatous polyps and adenocarcinomas; renal tubular cell adenomas and adenocarcinomas), unit risks were calculated using the linearized multistage [LMS] method of Howe (1995). An allometric scaling factor was applied to the final unit risks, assuming a rat weighs 0.35 kg, a mouse weighs 0.03 kg, and a human weighs 70 kg. The Kaplan-Meier mortality-adjusted data were not used, since using these data generally resulted in a worse fit while not appreciably changing the unit risk. The raw incidence data were used instead.

The multistage model was first fit to the bioassay data. The multistage model is given by

$$P(d) = 1 - e^{-q_0 - q_1 d - \ldots - q_k d^k}$$
where $d$ is dose, $k$ is the number of dose groups in the study (excluding control), $P(d)$ is the probability of the animal developing a tumour at dose $d$, and $q_i > 0$, $i = 0,...,k$ are parameters to be estimated.

The unit risk is defined as the increase in excess risk per unit dose, where excess risk is given by

\[
\frac{P(d) - P(0)}{1 - P(0)}
\]

The unit risk is applicable at very low doses, presumably in the range where humans will be exposed. For a small dose, $d$, the excess risk can be shown to be approximately equal to $q_i d$. Thus, when the background $P(0)$ is small, $q_i$ represents the slope (i.e., change in risk per increase of unit dose) of the dose–response curve in the low-dose region. In practice, the upper 95% confidence limit on $q_i$ is used and is denoted by $q_i^*$. This is the unit risk for the LMS method.

A chi-square lack of fit test was performed for the model fits. The degrees of freedom for this test are equal to $k$ minus the number of $q_i$s whose estimates are non-zero. A P-value less than 0.05 indicates a significant lack of fit. Some models exhibited a significant lack of fit, but since only three dose groups were present (including control), removing the highest dose group is unadvisable. Unit risks and lack of fit P-values are displayed in Appendix 1 of Health Canada (2003b).

The allometric scaling factor is given by $(0.35/70)^{1/4}$ or $(0.03/70)^{1/4}$, where 0.35 kg is the body weight of a rat, 0.03 kg is the body weight of a mouse, and 70 kg is the body weight of a human. The “raw” unit risks are divided by this factor to obtain the “converted” unit risks in Table 2 of Health Canada (2003b). Using the LMS model for the tumours that were significantly increased in F344/N rats in the NTP (1987) bioassay, the estimated calculated unit lifetime human cancer risks associated with the ingestion of 1 µg/L BDCM in drinking water range from $2.06 \times 10^{-7}$ (based on combined adenomatous polyps and carcinomas of the large intestine in females rats) to $6.33 \times 10^{-7}$ (based on combined adenomatous polyps and carcinomas of the large intestine in males rats).

In the context of drinking water guidelines, Health Canada has defined the term “essentially negligible” as a range from one new cancer above background per 100,000 people to one new cancer above background per 1 million people (i.e., $10^{-5}$ to $10^{-6}$) over a lifetime.

The estimated concentrations corresponding to lifetime human cancer risks of $10^{-5}$, $10^{-6}$, and $10^{-7}$ for these tumour types, based on the model described above and the calculated unit lifetime human cancer risks, are as follows:

<table>
<thead>
<tr>
<th>Lifetime risk</th>
<th>Concentrations in drinking water (µg/L)</th>
</tr>
</thead>
<tbody>
<tr>
<td>$10^{-5}$</td>
<td>15.8–48.5</td>
</tr>
<tr>
<td>$10^{-6}$</td>
<td>1.6–4.9</td>
</tr>
<tr>
<td>$10^{-7}$</td>
<td>0.2–0.5</td>
</tr>
</tbody>
</table>
Using the most conservative concentration in drinking water estimated for a $10^{-5}$ lifetime human cancer risk, a health-based target of 16 µg/L (rounded) is derived.

11.3 **Dibromochloromethane**  
DBCM has been classified in Group IIID, possibly carcinogenic to humans based on limited evidence for carcinogenicity in one species of experimental animals and no data in humans (Health Canada, 1994). An expert panel convened in 2002 by Health Canada to assess the toxicological and epidemiological evidence for the THMs for the purpose of drafting an updated Canadian drinking water guideline concluded that there was insufficient information available to calculate a drinking water guideline for DBCM (Health Canada, 2003b).

11.4 **Bromoform**  
Bromoform has been classified in Group IIID, possibly carcinogenic to humans based on limited evidence for carcinogenicity in one species of experimental animals and no data in humans (Health Canada, 1994). An expert panel convened in 2002 by Health Canada to assess the toxicological and epidemiological evidence for the THMs for the purpose of drafting an updated Canadian drinking water guideline concluded that there was insufficient information available to calculate a drinking water guideline for bromoform (Health Canada, 2003b).

12.0 **Rationale**  
Because THMs are formed in drinking water primarily as a result of chlorination of organic matter present in raw water supplies, it is important to recognize the substantial benefits to health associated with disinfection by chlorination. The use of chlorine has virtually eliminated waterborne microbial diseases, because of its ability to kill or inactivate essentially all enteric pathogenic microorganisms. Chlorine is the most convenient and easily controlled disinfectant; it is a strong oxidant for which a residual can be maintained in the distribution system to prevent bacterial regrowth. Although the use of chlorine can lead to the formation of disinfection by-products such as THMs, efforts to manage THM levels in drinking water must not compromise the effectiveness of disinfection.

THMs and haloacetic acids (HAAs) are the two major groups of CDBPs found in drinking water and generally at the highest levels. The concentrations of these contaminants can be used as indicators of the total loading of all CDBPs which may be found in drinking water supplies. In the absence of information on other CDBPs, control and management of THMs and HAAs should reduce exposure to and risk from other by-products. When appropriate drinking water treatment strategies are implemented to reduce THMs and HAAs, the levels of other chlorinated disinfection by-products may also be reduced in the process.

Two guidelines for trihalomethanes have been established. The THM guideline is based on health effects of chloroform, and applies to the total concentration of chloroform, BDCM, DBCM and bromoform. A separate guideline for BDCM was also established; BDCM can be used as an indicator of the presence of other brominated THMs in drinking water. Animal data have consistently shown significantly higher level of toxicity for brominated DBPs than chlorinated DBPs.
New information also indicates that inhalation and dermal absorption from drinking water are important exposure routes, and should be considered, resulting in a higher overall exposure to all THMs.

12.1 Trihalomethanes (chloroform)

Considerable progress has been made since the establishment of the previous Canadian drinking water guideline for THMs which was also based on chloroform. The weight of evidence now suggests that chloroform is a threshold carcinogen mediated through a non-genotoxic mechanisms of action resulting in sustained cytotoxicity by metabolites and ultimately persistent cellular proliferation (i.e., cancer). As such, chloroform has been reclassified from Group II (probably carcinogenic to humans) in the previous guideline to Group III (possibly carcinogenic to humans) in this assessment. Incorporation of additional exposure routes from drinking water such as inhalation and dermal absorption leads to a higher overall exposure (total of 4.11 Leq/day for ingestion and dermal and inhalation exposures from showering and bathing) to THMs than was previously recognized and results in a calculated health-based target of 80 µg/L. Chloroform was again used as a model THM for the purposes of derivation of a guideline since it is the THM for which there exists the most scientific information on which a guideline could be based, and it is also the predominant THM found in drinking water supplies.

Epidemiological evidence of a possible association between exposure to high levels of THMs and reproductive effects has also been reviewed. However, neither a dose-response pattern of increasing risk with increasing concentration of THMs nor a clear evidence of a threshold has been found.

Meeting a guideline of 80 µg/L for THMs in drinking water can present significant financial implications for treatment plants. As the increase in health risks from exposure to THMs at levels up to 100 µg/L is not expected to be significant, the Federal-Provincial-Territorial Committee on Drinking Water is establishing a MAC of 0.10 mg/L (100 µg/L) for THMs in drinking water, based on an annual average. Utilities should make every effort to achieve concentrations as low as reasonably achievable without compromising the effectiveness of water disinfection.

12.2 Bromodichloromethane

Because BDCM is classified in Group II (probably carcinogenic to humans), the MAC is derived based on consideration of the estimated lifetime cancer risk and best available treatment technology. Since the MAC must be measurable by available analytical methods, the Method Detection Limit (MDL) is also taken into consideration.

A MAC of 0.016 mg/L (16 µg/L) for BDCM is derived, on the basis of the following considerations:

(1) The estimated unit lifetime human cancer risk associated with the ingestion of 1 µg/L BDCM in drinking water ranges from $2.06 \times 10^{-7}$ (based on adenomatous polyps and carcinoma tumours [combined] of the large intestine in female rats) to $6.33 \times 10^{-7}$ (based on adenomatous polyps and carcinoma tumours [combined] of the large intestine in male rats). Therefore, the estimated lifetime human cancer risk associated with ingestion of 16 µg/L BDCM (i.e., $3.3 \times 10^{8}$ to $1.0 \times 10^{5}$ ) is within a range that is considered to be “essentially negligible.”
(2) The MDL (based on the ability of laboratories to measure THMs including BDCM within reasonable limits of precision and accuracy) is 0.1–0.2 µg/L, which is well below the MAC.

(3) The MAC must be measurable and achievable. By optimization of treatment processes (i.e., improvement of specific conventional water treatment processes to remove organic [brominated] compounds prior to disinfection and addition of such processes as carbon adsorption and preoxidation), BDCM concentrations can be reduced below 16 µg/L.

Epidemiological studies, partially supported by toxicological studies, have also identified possible associations of reproductive effects (increased risk for spontaneous abortion or stillbirth) with exposure to BDCM. Recent studies suggest that BDCM targets human placental trophoblasts that produce chorionic gonadotrophin, a hormone that plays a vital role in the maintenance of pregnancy. A decrease in bioactive levels of this hormone could lead to adverse effects on pregnancy; however, only limited evidence exists on the biological plausibility of the observed BDCM-induced pregnancy loss. Although the lowest levels of exposure to BDCM associated with possible fetal loss in epidemiological studies are ≥20 µg/L, the evidence is presently insufficient to determine whether BDCM in drinking water causes reproductive effects in humans, or to base the MAC on these effects. These epidemiological studies have been carefully reviewed and considered in the guideline development, both by the Federal-Provincial-Territorial Committee on Drinking Water and by the CDBP Task Group. From a risk assessment perspective, these epidemiological studies are considered limited in their ability to quantify individual exposure to BDCM or other specific disinfection by-products. It is recommended that utilities strive to keep levels of brominated THMs as low as reasonably achievable without compromising the effectiveness of disinfection.

As part of its on-going guideline review process, Health Canada will continue to monitor new research in this area and recommend any change(s) to the guideline it deems necessary.

13.0 References


Trihalomethanes (May 2006)


NCI (1976a) Carcinogenesis bioassay of chloroform. NTIS PB-264018/AS Carcinogen Bioassay and Program Resources Branch, National Cancer Institute, Bethesda, MD, March.

NCI (1976b) Report on carcinogenesis bioassay of chloroform. NTIS PB-264-018 National Cancer Institute, Bethesda, MD.


NTP (1985) Toxicology and carcinogenesis studies of chlorodibromomethane (CAS No. 124-48-1) in F344/N rats and B6C3F1 mice (gavage studies). NTP TR 282, National Toxicology Program, U.S. Department of Health and Human Services, Research Triangle Park, NC.

NTP (1987) Toxicology and carcinogenesis studies of bromodichloromethane (CAS No. 75-27-4) in F344/N rats and B6C3F1 mice (gavage studies). NTP TR 321, National Toxicology Program, U.S. Department of Health and Human Services, Research Triangle Park, NC.

NTP (1989) Toxicology and carcinogenesis studies of tribromomethane (bromoform) (CAS No. 75-25-2) in F344/N rats and B6C3F1 mice (gavage studies). NTP TR 350, National Toxicology Program, U.S. Department of Health and Human Services, Research Triangle Park, NC.


### Appendix A: List of acronyms

<table>
<thead>
<tr>
<th>Acronym</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>ALARA</td>
<td>as low as reasonably achievable</td>
</tr>
<tr>
<td>ANSI</td>
<td>American National Standards Institute</td>
</tr>
<tr>
<td>BDCM</td>
<td>bromodichloromethane</td>
</tr>
<tr>
<td>BrdU</td>
<td>5-bromo-2’-deoxyuridine</td>
</tr>
<tr>
<td>CDBPs</td>
<td>chlorinated disinfection by-products</td>
</tr>
<tr>
<td>CEPA</td>
<td>Canadian Environmental Protection Act, 1999</td>
</tr>
<tr>
<td>DBCM</td>
<td>dibromochloromethane</td>
</tr>
<tr>
<td>DBPs</td>
<td>disinfection by-products</td>
</tr>
<tr>
<td>DENA</td>
<td>diethylnitrosamine</td>
</tr>
<tr>
<td>DNA</td>
<td>deoxyribonucleic acid</td>
</tr>
<tr>
<td>EPA</td>
<td>Environmental Protection Agency (USA)</td>
</tr>
<tr>
<td>FLR</td>
<td>full litter resorption</td>
</tr>
<tr>
<td>GSTT1-1</td>
<td>glutathione-S-transferase T1-1</td>
</tr>
<tr>
<td>HAAs</td>
<td>haloacetic acids</td>
</tr>
<tr>
<td>IPCS</td>
<td>International Programme on Chemical Safety</td>
</tr>
<tr>
<td>kg bw</td>
<td>kilogram body weight</td>
</tr>
<tr>
<td>LD_{50}</td>
<td>median lethal dose</td>
</tr>
<tr>
<td>Leq/day</td>
<td>litre-equivalent per day</td>
</tr>
<tr>
<td>LH</td>
<td>luteinizing hormone</td>
</tr>
<tr>
<td>LMS</td>
<td>linearized multistage</td>
</tr>
<tr>
<td>LOAEL</td>
<td>lowest-observed-adverse-effect level</td>
</tr>
<tr>
<td>MAC</td>
<td>maximum acceptable concentration</td>
</tr>
<tr>
<td>MDL</td>
<td>method detection limit</td>
</tr>
<tr>
<td>NCI</td>
<td>National Cancer Institute (US)</td>
</tr>
<tr>
<td>NOAEL</td>
<td>no-observed-adverse-effect level</td>
</tr>
<tr>
<td>NOM</td>
<td>natural organic matter</td>
</tr>
<tr>
<td>NSF</td>
<td>NSF International</td>
</tr>
<tr>
<td>NTP</td>
<td>National Toxicology Program (US)</td>
</tr>
<tr>
<td>PBPK</td>
<td>physiologically based pharmacokinetic</td>
</tr>
<tr>
<td>ppm</td>
<td>parts per million</td>
</tr>
<tr>
<td>RNA</td>
<td>ribonucleic acid</td>
</tr>
<tr>
<td>SCC</td>
<td>Standards Council of Canada</td>
</tr>
<tr>
<td>SCE</td>
<td>sister chromatid exchange</td>
</tr>
<tr>
<td>TC_{05}</td>
<td>concentration associated with a 5% increase in tumour risk</td>
</tr>
<tr>
<td>TDI</td>
<td>tolerable daily intake</td>
</tr>
<tr>
<td>TGF</td>
<td>transforming growth factor</td>
</tr>
<tr>
<td>THMs</td>
<td>trihalomethanes</td>
</tr>
<tr>
<td>UDS</td>
<td>unscheduled DNA synthesis</td>
</tr>
<tr>
<td>UV</td>
<td>ultraviolet</td>
</tr>
<tr>
<td>WHO</td>
<td>World Health Organization</td>
</tr>
</tbody>
</table>